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ABBREVIATIONS AND SYMBOLS 
1D one-dimensional 
2D two-dimensional 
COSY correlated spectroscopy 
cryst crystallization 
δ chemical shift 
ESIMS electronspray ionization mass spectroscopy 
fr fraction 
HMBC heteronuclear multiple-bond correlation spectroscopy 
HSQC heteronuclear single-quantum coherence spectroscopy 
HPLC high-performance liquid chromatography 
HRE(S)IMS high-resolution electron (spray) ionization mass spectroscopy 
IR infrared 
JMOD J-modulated spin-echo experiment 
MDR multidrug resistance 
NMR nuclear magnetic resonance 
MS mass spectroscopy 
NOE nuclear Overhauser effect 
NOESY nuclear Overhauser enhancement spectroscopy 
NP normal-phase 
OCC open-column chromatography 
P-gp permeability glycoprotein 
PKC protein kinase C 
PLC preparative-layer chromatography 
RP reversed-phase 
RPC rotation planar chromatography 
TLC thin-layer chromatography 
tR retention time 
UV ultraviolet 
VLC vacuum-liquid chromatography 
Ester groups: Ac = acetyl, Bz = benzoyl, Nic = nicotinoyl, Prop = propanoyl, iBu = isobutanoyl, 
MeBu = 2-methylbutanoyl, iVal = isovaleroyl, Hex = hexanoyl 
2 
1. INTRODUCTION 
The family Euphorbiaceae is one of the largest families of flowering plants, composed of 5 
subfamilies, 49 tribes, over 300 genera and about 8000 species.1 The genus Euphorbia is one of the 6 
largest genera (Astragalus, Bulbophyllum, Psychotria, Euphorbia, Carex and Begonia) of flowering 
plants, with approximately 1830 species.2 The Euphorbia are widely distributed throughout both 
hemispheres and range in morphology from large desert succulents to trees, through climbing lianas 
and even some small herbaceous plant types.3 28 species of this genus have been found in Hungary.4 
The researched parts in various Euphorbia species include the roots, seeds, latex, lactiferous tubes, 
stem wood, stem bark, leaves and whole plants. 
Many Euphorbiaceae species are characterized by the occurrence of a highly irritant milky latex. 
These plants have been used to treat different cancers, tumours and warts since at least the time of 
HIPPOCRATES.5 The folk-medicinal uses of Euphorbia species include the treatment of infections, 
gonorrhoea, migraine, intestinal parasites, rheumatism, snake-bites, asthma, obstipation, coughs, 
sores and skin diseases.6 The family consists of species of great economic importance, such as 
Ricinus communis L. (castor oil), Croton tiglium (croton oil), Manihot esculenta Crantz (cassava, 
tapioca), Hevea brasiliensis Willd. ex. A. Juss (rubber tree), Euphorbia tetragonal and E. triangularis 
(inferior rubber), and Euphorbia resinifera (‘euphorbium’).7-9 Moreover, it includes noxious weeds 
such as Euphorbia esula L. and Euphorbia maculata L. Five species, E. pekinensis, E. kansui, E. 
lathyris, E. humifusa and E. maculata, have been recorded in Chinese pharmacopoeias for the 
treatment of oedema, gonorrhoea, migraine and wart cures, whereas these are well-known 
poisonous plants.10 
Diterpenes occurring in plants of the Euphorbiaceae family are of considerable interest from the 
aspect of natural product drug discovery because of the wide range of their potentially valuable 
biological activities and their broad structural diversity resulting from the variable acylation of many 
different skeletons (e.g. ingenane, tigliane, daphnane, lathyrane and jatrophane) with numerous 
aliphatic and aromatic acids. The importance of Euphorbiaceae diterpenes may be demonstrated 
primarily by the approval granted by the FDA in 2012 for the use of ingenol 3-angelate (ingenol 
mebutate, PEP005, Picato®, LEO Pharma) in the treatment of actinic keratosis, a precancerous skin 
condition. Besides ingenol 3-angelate, other promising compounds are currently subjects of drug 
development projects. Some phorbol and ingenol derivatives, and particularly prostratin, have 
become of considerable interest in HIV therapy: they reactivate HIV-1 latency by protein kinase C 
(PKC)-dependent NF-κB (nuclear factor) activation, and avoid the new infection of CD4+ cells.11 
Resiniferatoxin, a compound belonging in the daphnane group, is an ultrapotent capsaicin analogue, 
which is at present undergoing evaluation in phase II and III clinical trials.12 Moreover, antileukaemic 
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ingenane diterpenes have been obtained from Euphorbia esula, Croton tiglium and 
Cunuria spruceana. Further interesting diterpene esters with great structural variety and noteworthy 
biological activities have been isolated from Euphorbiaceae species.13-21 
In 1995, the workgroup of Department of Pharmacognosy, University of Szeged initiated a 
research programme with the aim of investigating the secondary metabolites of Hungarian 
Euphorbia species. In the course of these studies, many diterpene esters of different skeletal types 
have been isolated.22-33 One part of this programme involved the investigation of 
Euphorbia pannonica Host., E. esula L. and E. falcata L. The present thesis summarizes the results of 
these phytochemical works. 
1.1. Botany of the family Euphorbiaceae and the investigated Euphorbia species 
The Euphorbiaceae comprise one of the largest and most diversified families of angiosperms and, 
because of the range of morphological variation, may be polyphyletic in origin. There is great 
diversity in growth form, ranging from tall rain forest trees to lianas, shrubs, perennial and annual 
herbs, geophytes, succulents and floating aquatics.3 The tribe Euphorbieae is characterized by the 
possession of a unique cyathium, which consists of a central carpellate flower and 4 or 5 groups of 
basal male-flower clusters. Euphorbia plants are monoecious.34,35 
The investigated plants, Euphorbia pannonica, E. esula and E. falcata, belong in the section 
Tithymalus of the genus Euphorbia in the family Euphorbiaceae, in the order Euphorbiales. 
 
Euphorbia pannonica Host. (syn. Euphorbia nicaeensis All., E. goldei Prokh., E. stepposa Zoz ex 
Prokh., E. volgensis Krysht.) is a glabrous or minutely papillose, glaucous, often reddish-suffused 
perennial plant, up to 80 cm in height. It has 0–10(–20) axillary rays. The leaves, measuring 10–
75 × 3–18 mm, are lanceolate to oblong or occasionally ovate, nearly entire, obtuse, coriaceous, and 
3(–7)-veined. The ray-leaves are elliptic-ovate to suborbicular; the raylet-leaves are transversely 
ovate or reniform and often yellowish. The rays number (3–)5–18, and are once or twice 
dichotomous. The glands are truncate to emarginated or sometimes display 2 short horns. The 
capsule, measuring 3–4.5 × 3–4 mm, is shallowly sulcate, rugulose, and sometimes pubescent. The 
seeds are 2–2.5 mm in size, ovoid, nearly smooth, rarely indistinctly pitted and pale-grey. The plant 
inhabits dry and sunny places at altitudes between 100 and 1800 m, in degraded stages of 
Mediterranean Quercus forests.34-36 
 
Euphorbia esula L. (leafy spurge; syn. Euphorbia pseudovirgata (Schur) Soó, E. dalechampii Haw., 
E. discolor Led., E. intermedia Brebis, E. racemosa Tausch., E. tristis Bess., E. triumfetti Bert., 
Tithymalus esula Moench.) is a glabrous or pubescent perennial herb, up to 120 cm in height. 
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Stipules are absent, and the leaves are symmetrical at the base and stand opposite. The stems are 
usually unbranched at the base. It has up to 11 axillary non-flowering branches and 0–20(–30) 
axillary rays. The leaves, measuring 15–85 × 0.5–15 mm, are linear to broadly ovate or obovate, 
entire and bluish-green in colour, although they turn yellowish or reddish-orange in late summer. 
The ray-leaves are shorter and often wider than cauline. The glands have a truncated or 
emarginated outer margin or 2 horns. The horns of the glands are usually slender, or the outer 
margin of the glands is truncated or emarginated; the bracts between the male and female flowers 
are hirsute or plumose. The capsules measure 2.5–3 × 3.5 mm; they are deeply sulcated and 
granulated on the keels. The seeds measure 2 mm; they are ovoid, grey or brownish. This plant 
occurs in Europe, but only as an alien in the north, and in North America. It flowers from May to 
August.34-36 
 
Euphorbia falcata L. (syn. Euphorbia acuminata Lam.) is a glabrous, annual plant with a height of 40 
cm. The stems are simple or they have 2–3(–9) branches from the base, with 8–16 axillary rays. The 
leaves, measuring 5–30 × 3–5 mm, are obovate-spathulate to linear-oblong, cuneate, mucronate 
and entire. The ray-leaves are likely to be cauline. The raylet-leaves, measuring up to 21 × 10 mm, 
are asymmetrically suborbicular or elliptic-ovate, acuminate to aristate, and subentire. It has an 
umbel with 4–5 rays, up to 5 times dichotomous, the whole forming a cyathium. The glands are 
broad and have 2 horns. The capsules measure 1.5–2 × 1–2.5 mm; they are shallowly sulcate and 
smooth. The seeds measure 1.2 mm; they are flattened-ovoid-quadrangular, pale-grey or brown. 
This plant occurs in Europe.34,35 
1.2. Chemical constituents of the family Euphorbiaceae 
This group of plants has been the subject of intense phytochemical examinations. The isolated 
compounds include alkaloids (imidazoles, pyrimidines, pyrrolidines, pyridines, piperidines, 
quinolizidines, quinazolones, isoquinolines, morphinandienones, indoles, guanidines and diterpene 
alkaloids),36,37 sesqui-,38-40 di- and triterpenoids (tetra- and pentacyclic),41-43 flavonoids (particularly 
flavones, flavonols, and rarely flavanones),44,45 coumarins (in relatively few plants),46 lignans (in only 
2 genera: Jatropha and Phyllanthus)47, tannins (hydrolysable),48 phenanthrenes, quinones49 and 
other phenolic compounds,37 long-chain fatty alcohols (n-octacosanol and n-hexacosanol) and 
hydrocarbons, alkanes and amino acids. These compounds have been isolated from the latex and 
from different parts (the bark, cortex, flowers, leaves, roots and stems) of the plants. The most 
important constituents of the latex of many Euphorbia species are triterpenes and diterpenes, 
mainly in ester form.50 
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1.2.1. Diterpenoids of the family Euphorbiaceae 
Some diterpenes are ubiquitous (e.g. gibberellins) in the plant kingdom, whereas others have a more 
limited distribution. In particular, the macrocyclic diterpenes and their cyclization products display 
only a very limited distribution in the families Euphorbiaceae and Thymeleaceae. These diterpenes 
can be classified as ‘lower terpenes’ (e.g. ‘Euphorbiaceae diterpenes’), derived from a 
geranylgeranyl pyrophosphate precursor through a ‘head-to-tail’ cyclization (Figure 1).51 The 
functionalization of diterpenes presumably proceeds after cyclization. The cembrene cation is a very 
reactive intermediate containing a 14-membered ring, which stabilizes through the formation of 
cembranoids.52 The plants in the family Euphorbiaceae produce a great variety of diterpene esters, 
with various biological activities. Naturally occurring diterpenes isolated from the members of 
Euphorbiaceae up to 2006 were reviewed by REDEI and VASAS in their PhD theses.53,54 Up to 2006, 
more than 400 diterpenes were isolated from about 200 Euphorbia species, or their presence was 
detected. In 2008, SHI et al. reviewed the chemistry and pharmacology of the plants in the genus 
Euphorbia.55 Since that time, 196 new diterpenes have been isolated from 30 Euphorbia species. This 
section of my thesis is focused mainly on these diterpenoids and their pharmacological activities. 
Cembrane diterpenes have been isolated from different plants and marine invertebrates; many 
have cytotoxic56, antitumour57 or HIV-1-inhibitory58 activities. 
 
 
 
 
 
 
 
 
 
 
Figure 1. Hypothetical biogenic interconversions of diterpenes in the family Euphorbiaceae 
Large numbers of bicyclic diterpenes are to be found in the family Euphorbiaceae. The casbanes, 
formed from the cembrene cation by cyclization of the isopropanoyl group, have been considered to 
be precursors of a number of macrocyclic diterpenes.59 Casbanes with a trans or cis cyclopropane 
ring occur in the species of Euphorbia60,61 and other Euphorbiaceae genera.62,63 Some compounds 
have in vitro cytotoxic,56,59 antibacterial57 and antiproliferative57 activities. In 2009, LIANG et al. 
isolated a new casbane diterpenoid (pekinenal) with cytotoxic activity from E. pekinensis.10 The 
jatrophane ingenane tigliane 
geranylgeranyl 
pyrophosphate 
cembrene cation casbane lathyrane 
OPP
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bicyclic jatrophane diterpenes, with a bicyclo[10.3.0]pentadecane ring system, may be formed in the 
plant from a cembrene cation or a casbane precursor by rearrangement. Between 2008 and 2012, 
34 jatrophane and modified jatrophane diterpenes were isolated from Euphorbia species. The 
phytochemical investigation of E. guyoniana by El-Bassuony yielded guyonianin C and D.64 HEGAZY et 
al. also investigated the chemical constituents of E. guyoniana and isolated 2 new components, 
guyonianins E and F.65 Tuckeyanol A and B, and euphotuckeyanol were isolated from E. tuckeyana,66 
and further jatrophane diterpenoids (euphornin L and N) from E. helioscopia67,68. A new macrocyclic 
diterpenoid, named kansuinine J, was isolated from the roots of E. kansui. This compound is 
esterified with an isopentanoyl group; it was recently reported in jatrophane diterpenes for the first 
time.69 From the fruits of E. sororia, 6 new jatrophane diterpenes esterified with 6 or 7 acyl groups 
were isolated by HUANG et al.70 Phytochemical investigation of the whole plant resulted in 3 new 
jatrophane diterpenoids, sororianolides A–C.71 In 2011, 2 new jatrophanes were isolated from E. 
bungei.72 In addition to 2 known jatrophanes, a new jatrophane diterpenoid, euphopeplin A, was 
isolated from E. peplus.73 Finally, 6 new jatrophane diterpenoids were isolated from E. dendroides.74  
Many types of biological activities of jatrophanes have been reported, such as 
antiproliferative,65-67,71,75-77 cytotoxic,67 multidrug resistance (MDR)-reversing,74,78,79 anti-angiogenic,77 
antibacterial,64 antiviral,80 vasodepressor81 and anti-inflammatory.82 
Since the 1970s, more than 190 jatrophanes from natural sources have been identified. Their 
great structural variability stems from the number and positions of the double bonds, the nature 
and number of the oxygen functions, and the configuration of the diterpene core. The oxygen 
functions are hydroxy, keto, epoxy, ether or ester groups. Natural jatrophane diterpenes are mainly 
polyacylated derivatives. The number of ester moieties ranges between 283 and 8.65 The acyl 
residues are most frequently acetyl, benzoyl, isobutanoyl, 2-methylbutanoyl or nicotinoyl, and rarely 
propionyl, butanoyl, angeloyl, tigloyl or cinnamoyl. The most heterogeneously esterified molecules 
contain 4 different acyl groups,74 and there are only a few compounds with homogeneous ester 
groups.84 Depending on their substitution, jatrophanes may have 5–10 chiral centres. Jatrophane 
diterpenes do not form a stereochemically homogeneous series, because the configurations of the 
carbons are variable.  
Euphorbiaceae species synthesize different types of tricyclic diterpenes. One of the largest 
groups of tricyclic diterpenes are the lathyranes, which include about 90 compounds. The 
hydrocarbon nucleus of casbene and its saturated analogue, casbane, may be considered to be the 
biogenetic precursor of these diterpenes (Figure 1). Lathyrane diterpenes have been reported from 
E. lagascae (latilagascenes D–F),85 E. kansuensis,86 E. lathyris (euphorbia factor L8),
87-89 E. splendida,90 
E. helioscopia,91 E. bungei,72 E. aellenii92 and E. micractina.93 Interestingly, the lathyrane glucoside 
isolated from E. helioscopia is the only Euphorbia diterpene substituted with a sugar moiety.91 
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Latilagascenes A–E, isolated from E. lagascae are the first macrocyclic lathyrane diterpenes with an 
oxygen function at C-16. 
Pharmacological screening revealed that lathyrane-type compounds do not possess the pro-
inflammatory activity characteristic of other Euphorbiaceae diterpenes.94  
Ingols are 4,15-epoxy derivatives of lathyranes which have given rise to considerable interest as 
cytotoxic,95-97 vasoactive,17,98 antineoplastic,83 prostaglandin E2-inhibitory
99 and anti-HIV-1100 agents. 
Ingenol esters have been isolated from E. esula,101,102 E. kansui,103 E. ebracteolata,104-106 E. 
laurifolia and E. lactea.100 Five of the ingenane-type diterpenes isolated from E. cornigera97,107 were 
esterified with the rare anthraniloyl group. Some compounds exhibited molluscicidal activity.107 In 
2010, BALOCH et al. isolated 10 new ingenane-type esters from the latex of E. cauducifolia (syn. E. 
nerifolia). Interestingly, the diterpenes were substituted with acetyl, angeloyl, benzoyl and the rare 
palmitoyl and tetradecatrienoyl groups.108 
Tigliane, ingenane, daphnane, jatropholane, myrsinane, premyrsinane and rhamnofolane are 
further common types of ‘lower diterpenes’ with tri- or tetracyclic skeletons (Figure 2).51,109  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Skeletons of some common ‘lower diterpenes’ in the family Euphorbiaceae 
Compounds with tigliane, ingenane or daphnane skeletons have attracted interest because of 
their skin-irritant activities.59 The most exhaustively investigated tiglianes are phorbols esterified on 
C-12 and C-13, which activate PKC; they may therefore disturb the enzyme-regulated cellular 
activity. 12-O-Tetradecanoylphorbol 13-acetate has become a classical activator of PKC in many 
studies relating to signal transduction.110 Some tiglianes exert anti-HIV-1 activity.111,112 Tiglianes have 
been isolated from E. cornigera,113 E. macroclada114 and the fresh latex of E. cauducifolia.20 One of 
the phorboids isolated from E. macroclada was an A-seco-phorboid, an unprecedented type of 
tigliane daphnane ingenane 
myrsinane premyrsinane rhamnofolane 
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natural diterpenoids, while diterpenoids of E. cauducifolia were substituted with the rare N-(2-
aminobenzoyl) anthraniloyl moiety. Tiglianes have also been isolated from E. fischeriana,115 E. 
aellenii,116 E. dendroides74 and E. grandicornis.117 The structures of the 2 compounds of E. 
grandicornis differ from those of all previously known phorbol derivatives, since a 5-en-7-one or 5-
en-7-ol functionality is present in the molecule instead of the usual 6,7-olefin group. 
Premyrsinane diterpenoids have been isolated from E. macroclada114 and myrsinanes from E. 
aellenii and E. prolifera.118,119 Further tri- and tetracyclic diterpene types have been described from 
the family Euphorbiaceae. These minor diterpene classes are based on pepluane,18,120,121 segetane,122 
paraliane,123 jatrophatrione124 and euphoractine.125,126  
Among the diterpene constituents of the family Euphorbiaceae, non-specific ‘higher diterpenes’ 
may also be mentioned. The skeletons of these compounds are formed by the classical ‘concertina-
like’ cyclization typical of many diterpenoids, triterpenoids and steroids. Higher diterpenes, such as 
the bicyclic labdane127 and clerodane,128 the tricyclic abietane,129-133 and the tetracyclic bayerane,134 
kaurane133-136 and atisane137 types, occur in many other plant families, too. 
The absolute configurations of Euphorbia diterpenes have been investigated by X-ray analysis in 
only a few cases.119,138-142 The absolute configurations of all natural jatrophane derivatives are 
identical as concerns the ring anellation: H-4 is α, and 15-OH or the 15-acyl group is β-oriented. 
1.2.2. Chemical constituents of Euphorbia pannonica 
Phytochemical investigations of this plant have not been reported previously. 
1.2.3. Chemical constituents of Euphorbia esula 
Earlier chemical investigations of E. esula revealed 3 ingenane diterpenoids: ingenol 3,20-
dibenzoate, ingenol 3-dodecanoate, and ingenol 3-Δ2,4,6,8,10-pentene tetradecanoate.143,144 
Macrocyclic diterpenes, viz. jatrophane esters, esulons A, B, and C, with moderately toxic and mildly 
inflammatory effects, have been isolated from leafy spurge roots collected in North Dakota, and 
lathyrane and jatrophane triesters from seeds collected in Canada.16,145,146 In the course of our 
earlier work, 6 new jatrophane diterpenes, named esulatins A–F, were reported from the 
plant.22,147,148 In 2002, LIU et al. isolated 2 jatrophane diterpenes with cytotoxic activity from the 
whole herb collected in China.149 Later, ingenol esters were also isolated.101,102 From E. esula, tertiary 
and quaternary alkaloids, triterpenoids (24-methylenecycloartenol, cycloartenol, lupeol, lupeol 
acetate, α- and β-amyrin and δ-amyrenone),33 steroids (β-sitosterol)56 flavonoid glycosides 
(kaempferol 3-glucuronide), hydrocarbons, long-chain alcohols (1-hexacosanol and 1-
octacosanol),150 long-chain aldehydes (C26 and C28),
151 alkanes (C25-C30, n-triacontane, n-
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hentriacontane, n-dotriacontane and n-tritriacontane), L-inositol, gallic acid, amino acids152 and 
rubber have also been identified. 
1.2.4. Chemical constituents of Euphorbia falcata 
Chemical investigation of E. falcata yielded n-nonacosane, octadecan-2-one, eicosan-2-one, 
pentatriacontane, obtusifoldienol, γ-euphorbol and β-amyrin.153,154 Quercetin and its glycosides, 
myricetin, isomyricetin, gallic acid, 1-O-galloyl-β-D-glucose and 1-O-galloyl-4,6-
hexahydroxydiphenoyl-β-D-glucose were also detected in the plant.155,156 
1.3. Pharmacology of Euphorbia diterpenes 
Compounds isolated from different Euphorbia species exert many different activities, including 
antiproliferative, MDR-reversing, antimicrobial, vasoactive, immunomodulatory and anti-
inflammatory effects. 
1.3.1. Antitumour activity 
In the past few years, many investigations have been performed on the antitumour activity of 
Euphorbia diterpenes. Compounds with different skeletal types (e.g. casbane, abietane, ingenol, 
phorbol, lathyrane, myrsinane and jatrophane) proved to have moderate or strong antiproliferative 
effects on different human cancer cell lines (e.g. chronic myeloid leukaemia, nasopharyngeal, 
gastric, pancreatic, lung, ovarian and colon carcinomas). Some of them were reported to have 
cytotoxic activity, others inducing apoptosis. The mechanisms of actions were also investigated, and 
it was observed that diterpenes could be cytotoxic via inhibition of the activity of topoisomerase II 
and/or DNA synthesis or PKC modulation or the induction of apoptosis through either the inhibition 
of IL-6-induced and STAT3 activation or inhibition of the NF-κB signalling pathway. 
MIYATA et al. investigated the effects of ingenol diterpenes isolated from the roots of E. kansui on 
the proliferation activity of Xenopus embryo cells. Twelve diterpenes were isolated, and 8 of them 
induced the significant inhibition of cellular proliferation at low concentration. In order to determine 
the mechanism of action, the effects of these compounds on the activity of topoisomerase II were 
measured. It was concluded that most of the diterpenes that inhibited cellular proliferation also 
inhibited topoisomerase II activity.157 Later, YOSHIDA et al. studied the mechanism of inhibition of 
topoisomerase II activity and effects on the cell proliferation through DNA damage or the blockade 
of topoisomerase II by 20-O-(2’E,4’Z-decadienoyl)ingenol and 3-O-(2’E,4’Z-decadienoyl)ingenol. The 
conclusion was drawn that 20-O-(2’E,4’Z-decadienoyl)ingenol is a catalytic inhibitor of 
topoisomerase II. It brought about the growth arrest of mouse mammary tumour (MMT) cells in the 
G2/M phase of the cell cycle, without inducing γ-H2AX by DNA breaks.158 
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LUO et al. tested the cytotoxicity of jolkinolide B in human chronic myeloid leukaemia (K562), and 
observed that this compound displayed high activity against K562 cells, with an IC50 of 12.1 µg/mL.
159 
Later, WANG et al. investigated the molecular mechanism of the anti-cancer activity of jolkinolide B. 
It was found that it reduced cell viability and induced apoptosis in a dose- and time-dependent 
manner in human leukaemic cells (U937). The induction of apoptosis was accompanied by the 
downregulation of PI3K/Akt and the inhibition of apoptosis protein family proteins. Moreover, 
jolkinolide B treatment resulted in the activation of caspase-3 and -9.160 
The in vitro antiproliferative activities of helioscopinolide E and B, isolated from E. tuckeyana, 
were investigated by DUARTE et al. against 3 human gastrointestinal cancer cell lines: gastric (EPG85-
257), pancreatic (EPP85-181) and colon (HT-29) carcinomas. They were inactive against the colon 
carcinoma cell line (HT-29) and showed moderate growth inhibitory activity on the gastric (EPG85-
257) and pancreatic (EPP85-181) tumour cell lines.66 
The antitumour activities of 12-deoxyphorbol esters isolated from E. cornigera were investigated 
by BALOCH et al. Three compounds were cytotoxic, and displayed IC50 values of 0.8, 0.5 and 1.0 
µg/mL, respectively. The mechanisms of their action in the inhibition of DNA synthesis were also 
investigated and a significant correlation was found between the cytotoxicity and DNA cross-link and 
DNA strand-break formation.113 The levels of in vitro cytotoxicity of 2 ingenol derivatives isolated 
from E. cornigera were evaluated against RAW (mouse macrophage cells) and HT-29 (a colon cancer 
cell line) by the same group, using the MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] assay. 3-O-(2,3-Dimethylbutanoyl)-13-O-dodecanoyl-20-O-tetradecanoylingenol exhibited 
significant cytotoxicity, with IC50 = 5.0 μM (RAW) and 2.90 μM (HT-29). It was 5- and 1.5-fold more 
potent against RAW and HT-29 cancer cell lines than the standard amrubicin hydrochloride.97 
Investigation of the apoptosis-inducing mechanism of 17-hydroxyjolkinolide B (HJB) revealed that 
HJB strongly inhibits IL-6-induced and constitutive STAT3 (signal transducer and activator of 
transcription) activation. Furthermore, HJB directly targets the JAK (Janus kinase) family kinases, 
JAK1, JAK2, and TYK2, by inducing dimerization of the JAKs via cross-linking. The effect of HJB is 
specific, as it has no effect on the platelet-derived growth factor, epidermal growth factor, or 
insulin-like growth factor 1 signalling pathways.161 
YAN et al. investigated the antitumour effects of 17-acetoxyjolkinolide B and 6 analogues, isolated 
from E. fischeriana. It was concluded that these compounds irreversibly inhibit the NF-κB signalling 
pathway by interacting directly with IKK-β. Moreover, 17-acetoxyjolkinolide B induces apoptosis of 
tumour cells and acts synergistically with anticancer drugs such as doxorubicin.162 
SEROVA et al. investigated the effects of PKC modulation by ingenol 3-angelate (PEP005, ingenol 
mebutate) on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signalling in 
cancer cells, and concluded that both the AKT and Ras/Raf/MAPK pathways in Colo205 colon cancer 
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cells are differentially modulated by ingenol 3-angelate, and that only the latter is mediated by PKC 
isozymes.163 ERSVAER et al. later evaluated the balance between the efficacy and toxicity of ingenol 3-
angelate in the treatment of human cancer. This hydrophobic diterpene ester is strongly cytotoxic at 
high concentration (100 μg/mL), while at concentrations of 10–100 ng/mL it is a selective activator 
of PKC.164,165 Ingenol 3-angelate has both anticancer and proinflammatory effects, which is an 
advantage in topical skin application, but it can be dangerous in the event of systemic therapy. In 
conclusion, the authors established that extensive in vivo experimental models and carefully 
designed clinical studies can clarify whether the systemic use of this compound will be acceptable 
with regard to the risk of toxicity.166 
TAO et al. investigated the cytotoxic activity of jatrophane diterpenes, isolated from E. 
helioscopia, using HL-60 cells by the MTT method and A-549 cells by the SRB (sulphorhodamine B) 
method. Two compounds (euphornin L and euphoscopin F) exhibited cytotoxicity against HL-60, with 
IC50 values of 2.7 and 9.0 µM, respectively, while the other compounds were inactive.
67 Guyonianins 
E and F and 5,7,14-triacetoxy-3-benzoyloxy-15-hydroxy-9-oxojatropha-6(17),11E-diene isolated from 
E. guyoniana were investigated for cytotoxic activity by HEGAZY et al. 5,7,14-Triacetoxy-3-benzoyloxy-
15-hydroxy-9-oxojatropha-6(17),11E-diene exhibited significant activity (IC50 = 35 μM), and 
guyonianins E and F moderate activity (IC50 = 70 and 100 μM, respectively) against human embryonic 
kidney 293 (HEK293) cells.65 Investigation of the anticancer characteristics of euphodendrophane A 
and B on a sensitive non-small cell lung cancer cell line (NCI-H460) and its resistant counterpart (NCI-
H460/R) demonstrated that these compounds inhibited the growth of these cancer cells and were 
non-toxic for peripheral blood mononuclear cells (PBMS).77 
The cytotoxic activity of pekinenal was investigated against 4 human cancer cell lines, NCI-H460 
(lung), KB (nasopharyngeal), SGC7901 (gastric) and HO-8910 (ovarian), by the MTT assay. The 
compound exhibited cytotoxic activity, with IC50 values of 10.05, 8.52, 13.82, and 14.16 µg/mL, 
respectively.10 WANG et al. evaluated the cytotoxicities of compounds isolated from E. fischeriana 
against human cancer cell lines, MDA-MB-231 and HepG2, and a human immortalized cell line 
(HEK293). Only 12-deoxyphorbol-13-hexadecanoate was found to be cytotoxic against MDA-MB-231 
cells (IC50 = 6.694 μM).
115 In the following year, ZHANG et al. investigated the antiproliferative activity 
of euphorbia factor L3 against a lung cancer cell line (A549) in vitro. It was found to show potent 
cytotoxicity and to induce apoptosis via the mitochondrial pathway in A549 cells, with involvement 
of the loss of mitochondrial potential and the release of cytochrome C.89 The cytotoxicities of 
proliferins A, B and D, isolated from E. prolifera, were evaluated against various cancer cells (HCT-8, 
Bel-7402, BGC-823, A549 and A2780). Only proliferin A proved to be cytotoxic against A2780 human 
ovarian cancer cells (IC50 = 7.7 μM).
167 
12 
Human cytomegalovirus (CMV) preferentially infects tumour tissues, and the accumulated CMV 
immediate-early (IE) antigen may lead to tumour promotion and progression. The development of 
strategies to inhibit the human CMV IE antigen expression and/or function is an important goal as 
concerns the prevention and treatment of certain forms of cancers associated with human CMV. 
PUSZTAI et al. investigated the effects of the lathyrane-type latilagascenes A–E and jolkinol B on CMV 
IE antigen expression in lung cancer cells. It was concluded that latilagascene E demonstrated the 
highest activity, while latilagascene D was inactive.168 
1.3.2. Multidrug resistance-reversing activity 
MDR is a major obstacle in the chemotherapeutic treatment of cancer. MDR can be reversed by 
drugs that vary widely in their chemical structure and main biological action. Special attention is paid 
to P-glycoprotein (P-gp)-related MDR as the most experimentally and clinically tested form of drug 
resistance. P-gp, one of the most important and best-studied ABC transporter proteins, acts as an 
energy-dependent pump of chemotherapeutic agents, thereby decreasing the intracellular 
concentration of drugs and resulting in MDR. 
JIAO et al. investigated the MDR activities of lathyrane diterpenes isolated from E. lathyris on 
MCR7/ADM cell lines in vitro. It was concluded that the position of the double bond between C-6 
and C-7, and substitution on C-7 are important factors relating to the capability of inhibition. The 
most active compound was 7-hydroxylathyrol, while isolathyrol showed moderate activity. 
DUARTE et al. derivatized latilagascene B, previously isolated from E. lagasce, to yield 3 new 
lathyrane esters: latilagascene G, H and I. Their MDR-inhibitory activities were investigated together 
with those of tuckeyanols A and B, euphotuckeyanol, latilagascene A–F and jolkinol B. Structure–
activity relationship studies were also carried out.76 Later, they evaluated the MDR-reversing and 
apoptosis-inducing activities of latilagascenes A–F and jolkinol, isolated from E. lagascae. All these 
compounds were shown to enhance drug retention in the cells by inhibiting the efflux-pump activity, 
mediated by P-gp. Latilagascene E displayed the highest effect (FAR = 216.8, at 4 µg/mL; FAR is 
defined in section 5.4). Moreover, the in vitro effects of latilagascene B in combination with 
doxorubicin on human MDR1 gene-transfected mouse lymphoma cells were also examined. A 
synergistic interaction was observed between the 2 compounds (FIX = 0.292; FIX is defined in section 
5.4). In the case of apoptosis induction, it was found that latilagascene B was the most active at the 
highest concentration.85 LAGE et al. also investigated macrocyclic diterpenes (latilagascenes B, C and 
D, jolkinol B, ent-16α-hydroxyatisane-3-one and ent-16α,17-dihydroxykauran-3-one isolated from E. 
lagasce, and helioscopinolides A, B, D and E from E. tuckeyana, an acetylation reaction product of 
helioscopinolide B75 and acetylation products of ent-16α-hydroxatisane-3-one and ent-16α,17-
dihydroxykauran-3-one169) for their potential antineoplastic activity on gastric (EPG85-257), 
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pancreatic (EPP85-181) and colon (HT-29) human carcinoma cell lines. Furthermore, the effects of 
these diterpenes on different multidrug-resistant variants of these cancer cell lines over-expressing 
MDR1/P-gp or without MDR1/P-gp expression were also evaluated. The most active compounds 
were the lathyrane diterpenes latilagascenes C and D, and the diterpene lactones 3β-
acetoxyhelioscopinolide B and helioscopinolide E, which exhibited high antineoplastic activities 
against the drug-resistant EPG85-257 cell line. In addition, jolkinol B was found to be highly effective 
in the multidrug-resistant HT-29 cell line.169 
In the search for MDR-reversing compounds from natural sources, a series (n = 32) of Euphorbia 
diterpenes were tested by MOLNÁR et al. on mouse lymphoma cells, using the rhodamine 123 
exclusion test. The diterpenes investigated represented various skeletal types, e.g. jatrophanes, 
lathyranes and ’euphoractine-type’ compounds. The results showed that structurally different 
ditepene polyesters may display significant MDR-reversal effects.78 In another screening 
programme, COREA et al. investigated the MDR-modulatory activities of 62 diterpenes isolated 
previously from Euphorbia species (E. dendroides, E. characias, E. peplus, E. paralias and E. 
helioscopia). Since these compounds were based on a structurally homogeneous skeleton, with 
differences only in the substitution pattern, a structure–activity relationship study was possible. 
Among others, it was concluded that the presence of hydroxy groups on C-3 and C-15, acetyl groups 
on C-8 and C-9 and a keto group on C-14 in jatrophanes increased the anti-MDR activity, while the 
presence of a hydroxy group on C-2, an acetyl group on C-14, and nicotinoyl groups on C-5 and C-9 
reduced the inhibitory potency of the compounds.79 
In 2011, ZHANG et al. investigated the MDR-reversing potency and the detailed mechanisms of 
actions of euphorbia factor L1. It was concluded that this compound potentiated the sensitivity of 
the ABCB1 substrates investigated and increased the accumulation of doxorubicin and rhodamine 
123 in ABCB1-mediated MDR KBv200 and MCF7/adr cells. The activity of euphorbia factor L1 is 
related to its being a stimulator of ABCB1 ATPase activity and an inhibitor of the efflux of ABCB1 in 
KBv200 and MCF7/adr cells. Moreover, euphorbia factor L1 did not downregulate the expression of 
ABCB1 at either an mRNA or a protein level.170 
The effects of euphodendrophane A and B in combination with paclitaxel (PTX) were examined. 
These jatrophanes overcome PTX resistance in a concentration-dependent manner in MDR cancer 
cell line (NCI-H460/R), as they induce cell killing and change the cell cycle distribution, leading to a 
G2/M arrest. Furthermore, these compounds exert an anti-angiogenic effect by decreasing vascular 
endothelial growth factor secretion.74,77 
The MMP-2 and -9 (matrix metalloprotein)-modulating activities of diterpenes isolated from E. 
formosana on human fibrosarcoma cell line HT1080 were investigated by YU et al. Among them, 3-
hydroxy-ent-abietane compounds [helioscopinolide A–C and ent-(5β,8α,9β,10α,12α(-12-hydroxyatis-
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16-ene-3,14-dione)] significantly up-regulated the expressions of MMP-2 and -9 at concentrations of 
10 and 50 µM.132 
1.3.3. Immunomodulatory activity 
The immunomodulatory effect of 14-desoxo-3β,5α,7β,10,15β-O-pentaacetyl-14α-O-benzoyl-10,18-
dihydromyrinsol isolated from E. aellenii was investigated on the oxidative burst activity of whole-
blood phagocytes and the proliferation of human peripheral blood lymphocytes. In concentrations 
of 0.5, 5 and 50 μg/mL, the compound resulted in the dose-dependent suppression of T-cell 
proliferation by 39 ± 5.0, 68 ± 2.0 and 72 ± 1.6%, respectively.118 Later, the immunomodulating 
potentials of tigliane diterpenes isolated from E. aellenii were tested by GHANADIAN et al., using 
neutrophils of human whole blood. It was concluded that 4-deoxy-4α-phorbol-12-(2,3-
dimethyl)butyrate-13-isobutyrate exhibited moderate inhibitory activity against both T-cell 
proliferation and reactive oxygen species production, with IC50 = 14 and 44.1 μg/mL, respectively.
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The in vitro anti-inflammatory activities of 4 jolkinolides (jolkinolide A and B, and 17-hydroxy-
jolkinolide A and B) in lipopolysaccharide-stimulated RAW264 macrophages were investigated by 
UTO et al. Among them, 17-hydroxy-jolkinolide B (HJB) exhibited the most potent inhibition of the 
LPS-induced production of inflammatory mediators such as PGE2, NO, and pro-inflammatory 
cytokines IL-6 and TNF-α. These inhibitory effects were caused by the suppression of MAPK 
phosphorylation and NF-κB activation.171 
1.3.4. Anti-inflammatory activity 
Pepluanone, a diterpene component of E. peplus, possesses a high anti-inflammatory property in 
vivo. Furthermore, in vitro assays of pepluanone on LPS-stimulated J774 murine macrophages 
showed that it reduced the production of NO, PGE2 and TNF-α by reducing the expression of iNOS, 
COX-2 and TNF-α mRNA, respectively.172 BARILE et al. tested the anti-inflammatory activities of 
compounds with pepluane and paraliane skeletons, isolated from E. paralias. In this assay, one of 
the isolated compounds showed high activity, comparable to that found for pepluanone.123 
NUNOMURA et al. investigated the effects of 3-O-(2,3-dimethylbutanoyl)-13-O-decanoylingenol 
(DBDI), isolated previously from the roots of E. kansui,173 on the activation of intracellular signalling 
pathways and the release of inflammatory chemical mediators in bone marrow-derived mouse mast 
cells (BMMCs) upon FcεRI stimulation. It was revealed that DBDI significantly inhibits the [Ca2+]i 
increase, the β-hexosaminidase release and the synthesis of PGD2, PGE2 and LTC4 in BMMCs 
stimulated with IgE and multivalent antigen complex. Moreover, they demonstrated that DBDI 
inhibits the activation of intracellular signalling molecules, including Syk, PLC-γ2 and ERKI/2.174 
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In 2010, CHANG et al. reported that IL-6-induced Stat3 activation was inhibited by kansuinine A 
and B in HepG2 cells. Moreover, they established that ERK1/2 activation by these compounds could 
be a key player for the downregulation of IL-6-induced Stat3 activation.82 
1.3.5. Antiviral activity 
The persistence of latent HIV-infected cellular reservoirs is the major hurdle to virus eradication in 
patients treated with highly active antiretroviral therapy. Prostratin and other non-tumourigenic PKC 
agonists reactivate HIV-1 latency in vitro by activating NF-κB through a PKC-dependent pathway. The 
effects of extracts and fractions from the latex of E. laurifolia and E. lactea on HIV-1 reactivation in 
Jurkat-LAT-GFP cells were evaluated by AVILA et al. 3,12-Di-O-acetyl-8-O-tigloylingol, isolated from E. 
lactea, was able to reactivate HIV-1 latency in a concentration-dependent manner. Other 
investigated compounds were significantly less active. Due to the structural similarity between 3,12-
di-O-acetyl-8-O-tigloylingol and phorbol esters such as PMA and prostratin, the role of PKC in 3,12-
di-O-acetyl-8-O-tigloylingol-induced HIV-1 reactivation was studied. It was concluded that 3,12-di-O-
acetyl-8-O-tigloylingol reactivates HIV-1 through a PKC-dependent pathway.100 
BEDOYA et al. investigated the antiviral activity of a series of previously isolated jatrophane 
diterpenes. It was found that one of the compounds, SJ23B, exerted potent antiviral activity through 
the downregulation of HIV receptors and the induction of viral reactivation. In this investigation, the 
activity of SJ23B was 10-fold more potent than that of prostratin. Moreover, this compound 
activated PKC and was able to activate cells where HIV is hidden as a latent provirus.80 
TIAN et al. investigated the antiviral activities of lathyrane diterpenoids. It was established that 
15-cinnamoyloxylathyra-5,12-dien-3-ol-14-one showed in vitro activity against HIV-1 replication 
(IC50 = 8.2 μM).
93 
1.3.6. Antibacterial activity 
Screening of the in vitro antibacterial activities of guyonianin C and D by EL-BASSOUNY on Gram-
positive (Bacillus cereus and Staphylococcus aureus) and Gram-negative (Serratia sp. and 
Pseudomonas sp.) bacteria, demonstrated that guyonianin C possesses activity against B. cereus.64 
1.3.7. Vascular-relaxing activity 
Lathyrane diterpenoids isolated from E. micractina displayed significant vascular-relaxing activities 
against phenylephrine-induced vasoconstriction, with relaxation rates of 41–53%; the positive 
control verapamil exhibited a 44% relaxation at the same concentration.93 In 2006, BARLA et al. 
isolated a jatrophane diterpene ester from the aerial parts of E. helioscopia, which was found to 
have mild vasodepressor activity.81 
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1.3.8. Proinflammatory activity 
SHU et al. investigated the proinflammatory constituents of E. kansui. The results showed that 
kansuinines A and B and 3-O-(2’E,4’Z-decadienoyl)-20-O-acetylingenol markedly promoted 
proliferation of the splenic lymphocytes of exoteric mice and NO production by rat peritoneal 
macrophages at concentrations from 0.78 to 12.50 μg/mL. The three compounds are therefore 
believed to be important proinflammatory components of the roots of E. kansui.175 It was also 
reported that kansuinines A and B had antiviral and anticancer activities,176,177 indicating that these 
compounds are responsible for both pharmacological activity and toxicity. 
1.3.9. Pesticidal activity 
The MeOH extract of the roots of E. kansui exerted pesticidal activity against the brown plant 
hopper (Nilaparvatal ugens Stal) and the two-spotted spider mite (Tetranychus urticae Koch). 
Bioassay-guided fractionation led to the isolation of 3-O-(2,3-dimethylbutanoyl)-13-O-
dodecanoylingenol and 3-O-(2’E,4’Z-decadienoyl)ingenol.19 The 2 diterpenes showed greater activity 
against the brown plant hopper as compared with anise oil and eugenol. The calculated LD50 doses 
were 0.139 μg/insect for 3-O-(2,3-dimethylbutanoyl)-13-O-dodecanoylingenol and 0.111 μg/insect 
for 3-O-(2’E,4’Z-decadienoyl)ingenol. 
GENG et al. investigated the feeding deterrent activities of diterpenes isolated from E. fischeriana. 
Jolkinolide B and hydroxyjolkinolide B possessed strong feeding deterrent activities against 
Sitophilus zeamais (EC50 = 342.1 and 543.9 ppm, respectively) and Tribolium castaneum adults 
(EC50 = 361.4 and 551.5 ppm, respectively).
136 
1.3.10. Molluscicidal activity 
BALOCH et al. investigated the molluscicidal activities of extracts (CCl4, Et2O, CHCl3, Me2CO, EtOAc, 
EtOH and MeOH) of the roots of E. cornigera, on the freshwater snail Biomphalaria glabrata, an 
intermediate host of Schistosoma mamsoni. Bayluscide was used as positive control. The Me2CO 
extract displayed significant activity (IC50 = 15.5 µg/mL). Further purification of this extract resulted 
in the isolation of 10 ingenol-type diterpene polyesters. Eight of the isolated compounds exhibited 
relatively high activity against the intermediate snails.107 Later, BALOCH et al. investigated the 
molluscicidal effects of 8 phorbol derivatives isolated from E. cauducifolia against B. glabrata snails. 
Two compounds, with an acetyl or an N-(2-aminobenzoyl)anthraniloyloxy moiety at C-13, had higher 
activities than that of bayluscide, while other compounds were equipotent to the control 
niclosamide. The compounds probably induce osmosnailic instability and surface vesiculation, 
leading to the death of the snails.20 
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1.4. Folk-medicinal use of the investigated Euphorbia species 
As concerns E. pannonica, neither any folk-medicinal use nor any pharmacological investigation has 
yet been published. 
E. esula is toxic to livestock, and allelopathic to desirable forage plants.150 It is known to cause 
sheep mortality and to produce inflammation with the loss of hair from the feet of horses. The latex 
causes blistering with severe irritation if allowed to remain on the skin, and it can lead to partial 
blindness if dropped into the eyes.144 Extracts of the plant have been widely used in folk medicine to 
treat various cancers, swellings and warts.5 The main traditional uses were proved by 
pharmacological investigations. Previous pharmacological studies demonstrated the 
proinflammatory, tumour-promoting and antitumour activities of the plant extracts.178-180 The 
extracts of E. esula exhibited antileukaemic activity against P-388 lymphocytic leukaemia in mice.143 
E. falcata has not been used in traditional medicine. 
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2. AIMS OF THE STUDY 
The Euphorbia genus is the source of a large number of biologically active diterpenes. In 1995, 
HOHMANN et al. (Department of Pharmacognosy, University of Szeged) initiated a research 
programme with the aim of investigating the secondary metabolites of plants of the Euphorbia 
species. The aims of the present work, as part of that programme, were the isolation and structural 
characterization of new diterpene polyesters, and investigation of their pharmacological effects. 
In order to achieve these aims, the main tasks were: 
− Screening of E. pannonica and E. falcata for diterpene content. 
− Extraction of the plant materials. 
− Isolation and purification of the diterpene esters from E. pannonica, E. esula and E. falcata 
by a combination of various chromatographic methods (OCC, VLC, RPC, PLC and HPLC). 
− Characterization and structure determination of the isolated compounds by different 
spectroscopic techniques (NMR and HR-MS). 
− Evaluation of the pharmacological potential and chemotaxonomical relevance of the 
isolated diterpenes. 
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3. MATERIAL AND METHODS 
3.1. Plant material 
E. pannonica: Aerial parts (5.1 kg) were collected in the flowering period from wild stock near 
Kiscsala-Császártöltés, Hungary, in June 2005. The plant material was identified by Dr. Tamás Rédei 
(Institute of Ecology and Botany of the Hungarian Academy of Sciences, Vácrátót, Hungary). 
E. esula: Whole plants (8 kg) were collected in June 2004 on the banks of the River Tisza, in Szeged, 
Hungary, and identified by Dr. Tamás Rédei. The fresh plant material was frozen and stored at -20 °C 
until preparation. 
E. falcata: Whole plants (20 kg) were collected in September 2008 in Mosonmagyaróvár, Hungary. 
The plant material was identified by Dr. Gyula Pinke (Department of Botany, Faculty of Agricultural 
and Food Sciences, University of West Hungary, Mosonmagyaróvár, Hungary). The fresh plant 
material was frozen and stored at -20 °C until preparation. 
3.2. Screening of plant material for diterpene content 
20 g each of fresh and crushed plant materials (E. pannonica and E. falcata) were percolated with 
200 mL of MeOH at room temperature. After concentration (to 30 mL), 30 mL of H2O was added to 
the extract and the mixture was subjected to solvent partitioning with 4 x 30 mL of CH2Cl2. The 
CH2Cl2-soluble phase was subjected to polyamide (1 g) OCC, using a solvent system of MeOH–H2O 
[1:4, 2:3, 3:2 and 4:1 (200 mL of each mixture)] as eluent. The fractions were concentrated and 
monitored by TLC, using a mobile phase of cyclohexane–EtOAc–EtOH (30:10:1) and CHCl3–Me2CO 
(19:1). 
Mobile phases in all types of chromatography methods are given in terms of volume ratio, v/v. 
3.3. Extraction and isolation of diterpenes 
3.3.1. Extraction 
The fresh E. pannonica, and the frozen E. esula and E. falcata plant material were crushed with a 
Waring CB-6 commercial blender (model 33BL13). The raw materials were percolated with MeOH 
(30 L, 60 L and 178 L) at room temperature in a glass percolator (diameter 15 cm, height 35 cm). The 
extracts were concentrated using a Rotavapor R-210 (40 °C, 337 mbar). H2O (500 mL, 1 000 mL and 
2 500 mL) was added to the extracts after concentration, and solvent–solvent partition was then 
performed with CH2Cl2 in the cases of E. pannonica and E. esula (5 × 1 000 mL and 5 × 1 500 mL) and 
with CHCl3 for the E. falcata (15 × 2 000 mL) mixture. 
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3.3.2. Isolation and purification of compounds 
Open-column chromatography: OCC was performed on polyamide for column chromatography (ICN) 
(113 g for the E. pannonica extract, 500 g for the E. esula extract and 1 100 g for the E. falcata 
extract). Mixtures of MeOH–H2O [2:3, 3:2, 4:1 (E. pannonica 4 L, E. esula 5 L and E. falcata 10 L of 
each)] were used as mobile phase for the plant extracts, with the exception of E. esula, where the 
elution was performed with MeOH–H2O (1:4) in the first step. 
Vacuum-liquid chromatography: For VLC, silica gel 60 GF254 (15 µm, Merck 11677) was used. The 
dissolved extracts were added to one-tenth of the silica gel. After drying, the powdery materials 
were placed on the remainder of the stationary phase in a filter funnel. The VLC columns were 
developed under gentle vacuum, provided by a water pump. Elutions were performed with a 
stepwise gradient. 
Rotation planar chromatography: RPC was carried on a Harrison Model 8924 Chromatotron 
instrument (Harrison Research). The stationary phase for RPC was silica gel 60 GF254 (Merck 7730), 
manually coated on the rotor as a 1 or 2 or 4 mm layer. The separation by RPC was achieved with 
gradient elution in 5 or 6 steps. The flow rates were from 4 to 8 mL/min. 
Preparative layer chromatography: PLC was performed on 20 × 20 cm silica plates (silica gel 60 F254, 
Merck 5715). The plates were developed by an ascending technique in a glass chamber at room 
temperature. Separation was monitored in daylight after spraying the border of the plates with 
conc. H2SO4 (then heating at 110 °C for 5 min) or in ultraviolet (UV) light at 254 nm. Compounds 
were eluted from the scraped adsorbent with CHCl3. 
The whole isolation procedure was monitored by using TLC on silica gel 60 F254 (Merck 5554). The 
visualization methods involved UV light at 254 nm, after spraying with conc. H2SO4, and then heating 
at 110 °C for 5 min; the spots were visualized in daylight. 
High-performance liquid chromatography: HPLC was carried out on a pre-packed Hibar RT (250 mm, 
4 mm) LiChrospher Si 100 (5 µm) column (Merck), on a pre-packed Hibar RT (250 mm, 10 mm) 
LiChrospher RP–18 (10 µm) column (Merck) and on a pre-packed Hibar RT (250 mm, 4 mm) 
LiChrospher RP–18 (5 µm) column (Merck), using a Waters instrument: Controller 600, a Pump 600, 
a Dual λ Absorbance Detector 2487, a Photodiode Array Detector 2998, and an Injector Rheodine 
7725i. Chromatographic separations were monitored at 254 and 288 nm. 
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3.4. Characterization and structure determination of the isolated compounds 
ESIMS measurement was carried out on an Applied Biosystems 3200 QTap spectrometer in ion trap 
mode. The HREIMS measurements were made on a VG-ZAB-SEQ sector instrument with an electron 
impact ion source. The resolution of the instrument was 10 000. The HRESIMS data were recorded, 
in the cases of E. esula, on a Shimadzu IT-TOF and for the E. falcata, on a Waters-Micromass Q-TOF 
spectrometer. Both instruments were equipped with electrospray source. 
NMR spectra were recorded on a Bruker DRX 500 spectrometer at 500 MHz (1H) and 125 MHz (13C), 
and a Bruker DRX 600 spectrometer at 600 MHz (1H) and 200 MHz (13C), with CDCl3 or MeOD as 
solvent and tetramethylsilane (TMS) as internal standard. Two-dimensional (2D) experiments were 
performed with standard Bruker software. 
Optical rotation values were determined in CHCl3 by using a Perkin-Elmer 341 polarimeter. 
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4. RESULTS 
4.1. Screening of E. pannonica and E. falcata for diterpene contents 
The extraction and sample preparation were carried out as described in section 3.2. As concerns the 
screening results on E. pannonica and E. falcata, the TLC chromatograms of fractions eluted with 
MeOH–H2O (3:2) (E. pannonica) and (2:3) and (3:2) (E. falcata) yielded brown, purple, blue and black 
spots of diterpenes with Rf values of 0.07–0.89 [mobile phase: cyclohexane–EtOAc–EtOH (30:10:1)]. 
The fractions eluted with MeOH–H2O (4:1) contained mainly triterpenes and fats. These 
observations led to the conclusion that the extracts of E. pannonica and E. falcata contain a series of 
different diterpene esters, which can be enriched in the 40% and 60% MeOH fractions of the apolar 
extracts of the plants. 
4.2. Isolation of diterpenes 
4.2.1. Isolation of diterpenes from E. pannonica 
The aerial parts of E. pannonica (5.1 kg) were milled and percolated with MeOH (30 L) at room 
temperature. The MeOH extract was evaporated, using a Rotavapor (40 °C, 337 mbar). The extract 
was then subjected to solvent–solvent partitioning with CH2Cl2 to remove polar compounds (Figure 
3). The organic phase was concentrated. This residue (56.6 g) was dissolved in CH2Cl2 and adsorbed 
onto a polyamide stationary phase (113 g) to remove chlorophyll and triterpenes from the extract. 
The stationary phase was previously suspended in 40% MeOH (1 L). The diterpenoids were eluted 
from the polyamide sorbent with MeOH–H2O (2:3, 3:2, 4:1, v/v; 4 L each). Normal-phase (NP)-TLC 
analysis indicated that the fraction eluted with MeOH–H2O (3:2) contained a series of diterpenoids, 
which were separated by further chromatographic procedures. 
The diterpene-containing fraction was evaporated to dryness (3.2 g). This fraction was subjected 
to silica gel VLC, using a gradient system of cyclohexane–CHCl3–Me2CO (3:2:0, 1:1:0, 2:3:0, 3:7:0, 
1:4:0, 10:40:1, 4:16:1 and 1:4:1,). 50 mL fractions were collected. Combined fractions 17–33 (0.25 g) 
were further fractionated by RPC, using a gradient system of n-hexane–EtOAc mixtures (19:1, 9:1, 
17:3, 4:1, 3:1 and 7:3, v/v; 60 mL each, flow = 7 mL/min, 2 mm layer). The fractions containing 
diterpenes (fractions I and II) were separated on RPC, using a cyclohexane–EtOAc gradient system 
(100:0, 49:1, 19:1, 93:7, 9:1 and 17:3). Subfractions 74–76 of fraction I were further purified by 
preparative TLC on silica gel with cyclohexane–EtOAc (4:1). Final purification was carried out by 
reversed-phase (RP) preparative TLC with a solvent system of MeCN–H2O (4:1) to afford 4.2 mg of 
EPAN-3 (1). Subfractions 29–37 from the RPC separation of fraction II were subjected to preparative 
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TLC with n-hexane–CHCl3–Me2CO (50:50:3), and finally purified by RP-HPLC, using MeCN–H2O (13:7) 
as mobile phase (flow = 1.2 mL/min; tR = 8.3 min) to yield 3.6 mg of EPAN-7 (2). 
 
 
Figure 3. Isolation of diterpenes from E. pannonica 
4.2.2. Isolation of diterpenes from E. esula 
The whole fresh plants of E. esula (8 kg) were percolated with MeOH at room temperature. After 
concentration under vacuum, the crude extract was diluted with H2O and subjected to solvent 
partitioning to yield a CH2Cl2-soluble phase and an H2O-soluble phase (Figure 4). The concentrated 
dark-green organic phase (90 g) was chromatographed on a polyamide column. The combined 
fractions 16–37, obtained with a mixture of MeOH–H2O (1:4), were subjected to silica gel VLC, using 
a gradient system of cyclohexane–EtOAc–EtOH (from 9:1:0 to 1:1:1). Fractions 20–23 and 24–30 
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(1 048 mg) obtained with cyclohexane–EtOAc–EtOH (80:20:1 and 70:30:1) afforded a crystalline 
material upon standing, which was recrystallized from MeOH to yield EUP-13 [(10), 105 mg]. 
Combined fractions 24–30 were subjected to silica gel RPC, using a gradient system of cyclohexane–
EtOAc–EtOH (from 80:20:0.5 to 30:10:1). Fractions 37–48 (102.8 mg) were transferred repeatedly to 
a silica gel RPC and successively eluted with benzene–CH2Cl2–Et2O (from 2:1:0.5 to 1:1:2). From 
fractions 25–28, obtained with benzene–CH2Cl2–Et2O (2:1:1), 11.8 mg of EUP-23 (7) was obtained as 
crystals, and from fractions 29–41, eluted with benzene–CH2Cl2–Et2O (2:1:1), the yield of EUP-20 (3) 
was 5.7 mg. 
 
 
Figure 4. Isolation of diterpenes from E. esula 
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Fractions 31–62 (2.835 g) were fractionated by RP-VLC, using a gradient system of MeOH–H2O 
(from 3:2 to 1:0). From the resulting fractions 20–24 (1022.3 mg) on elution with MeOH–H2O (7:3), 
EUP-26 [(9), 10.0 mg] was crystallized. 
Fractions 63–72 (0.966 g) were subjected to silica gel RPC, using a gradient system of 
cyclohexane–EtOAc–EtOH (from 1:1:0 to 1:1:1). Fractions from cyclohexane–EtOAc (1:1), 5–11 
(82.4 mg) and 12–21 (55.1 mg), were further fractionated. Fractions 5–11 were eluted by RP-HPLC 
with MeCN–H2O (6:4) as eluent at a flow rate of 1.0 mL/min. Purification of the compound observed 
at tR = 11.4 min yielded EUP-18 [(6), 3.9 mg]. Fractions 12–21 were further purified by preparative 
TLC on silica gel, using cyclohexane–EtOAc–EtOH (5:5:2) as solvent, and followed by HPLC, using a RP 
column and MeCN–H2O (6:4) as eluent, to yield 30 mg of EUP-17 (11). 
The combined fractions 38–44 (2.600 g) obtained from the polyamide column with H2O–MeOH 
(3:2) were subjected to silica gel VLC, using a gradient system of cyclohexane–EtOAc–EtOH (from 
30:10:1 to 5:5:4). The resulting fractions 6–12 (817.3 mg), eluted with cyclohexane–EtOAc–EtOH 
(30:10:1), were subjected to silica gel RPC, using a gradient system of cyclohexane–EtOAc–EtOH 
(from 40:10:0 to 30:10:1). Fractions 39–51 (34.5 mg) and 52–54 (89.6 mg) were obtained with the 
70:20:2 and 30:10:1 eluents. These fractions were further chromatographed by RP-HPLC, using 
MeOH–H2O (7:3) as eluent at a flow rate of 3.0 mL/min. The compounds observed at tR of 23.7 min, 
26.1 min and 35.4 min yielded EUP-28 [(4), 17.6 mg], EUP-32 [(5), 5.2 mg] and EUP-29 [(8), 25.0 mg], 
respectively. 
4.2.3. Isolation of diterpenes from E. falcata 
The fresh plant material (20 kg), which was stored at -20 °C before processing, was crushed in a 
blender and then percolated with MeOH (178 L) at room temperature. The crude extract was 
concentrated in vacuum and subjected to solvent–solvent partitioning with CHCl3 (30 L) (Figure 5). 
On evaporation, an organic phase residue of 344 g was obtained, which was chromatographed on a 
polyamide column (1 100 g) with mixtures of H2O–MeOH (3:2, 2:3 and 1:4) as eluents. The fractions 
obtained with H2O–MeOH (3:2 and 2:3) were combined and subjected to silica gel VLC, using a 
gradient system of cyclohexane–EtOAc–MeOH (from 8:2:0 to 0:0:1). The OCC fractions were 
combined into 6 fractions according to the TLC monitoring. 
From fractions 9–14 (0.49 g), obtained with cyclohexane–EtOAc–MeOH (7:3:0), EFAL-3 (12) was 
crystallized. It was further purified on NP-TLC, using n-hexane–Me2CO (7:3), to yield 24.8 mg of 
EFAL-3. The mother liquor of compound EFAL-3 was subjected to RPC, eluted with cyclohexane–
CH2Cl2–MeOH of increasing polarity (from 80:20:1 to 60:50:3; layer thickness: 2 mm, flow rate: 7 
mL/min). Fractions 58–67 (148.9 mg), eluted with cyclohexane–CH2Cl2–MeOH (60:30:2), were 
further separated on RP-VLC with MeOH–H2O (from 1:1 to 85:15). Fractions 25–26 (25.6 mg) obtain- 
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Figure 5. Isolation of diterpenes from E. falcata 
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ed with MeOH–H2O (4:1) were purified by preparative NP-TLC, with n-hexane–Me2CO (3:2) as 
developing system, and finally by preparative NP-TLC with CHCl3–Me2CO (49:1), to yield compounds 
EFAL-4 [(13), 3.7 mg], EFAL-6 [(14), 3.2 mg] and EFAL-7 [(15), 3.5 mg]. 
Fractions 15–18 (0.98 g) were separated by RPC, using cyclohexane–CH2Cl2–MeOH of increasing 
polarity as solvent system (from 70:20:1 to 60:50:3; flow rate: 8.4 mL/min, layer thickness: 4 mm). 
Fractions 24–33 (0.40 g; compositions of the eluent: 70:20:2 and 70:30:2) were purified by 
preparative RP-HPLC at a flow rate of 2.5 mL/min, using a gradient MeOH–H2O solvent system (0–15 
min 55:45, 15–25 min by gradation 9:1, 25–40 min 9:1, 40–45 min by gradation 55:45, 45–65 min 
55:45). The fraction (119 mg) at tR = 31.0 min was subjected to TLC [MeOH–H2O (9:1) then n-
hexane–Me2CO (7:3)] to afford EFAL-20 [(17), 10.6 mg]. The fraction (67 mg) at tR = 32.0 min was 
purified by NP-TLC [n-hexane–Me2CO (7:3), then cyclohexane–EtOAc–EtOH (70:30:1)]. It was then 
separated by NP-HPLC at a flow rate of 1 mL/min, using n-hexane–Me2CO (7:3) as solvent system, to 
yield 4.9 mg of EFAL-19 [(16), tR = 11.4 min]. The fraction (7.5 mg) at tR = 12.4 min was further 
chromatographed by RP-HPLC at a flow rate of 0.5 mL/min, using MeOH–H2O (3:1), and the 
compound at tR = 35.0 min was isolated as EFAL-21 [(18), 4.8 mg]. 
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4.3. Characterization and structure determination of the isolated compounds 
The structure elucidation was performed by means of NMR and mass spectroscopy (MS). Table 1 
lists some physical characteristics for the isolated compounds, such as optical rotation data and 
melting points. 
Table 1. Yields and physical data on the isolated compounds 
Compound Yield (mg) Optical rotation [° (t) (c)] M.p. (°C) 
EPAN-3 (1) 4.2 -20 (t1) (0.04) - 
EPAN-7 (2) 3.6 No Data  - 
EUP-13 (10) 105.0 +5 (t2) (0.1) 262-268 
EUP-17 (11) 30.0 -101 (t2) (0.12) 134-138 
EUP-18 (6) 3.9 -140 (t3) (0.1) - 
EUP-20 (3) 5.7 -4 (t3) (0.1) - 
EUP-23 (7) 11.8 -82 (t3) (0.1) - 
EUP-26 (9) 10.0 -10 (t4) (0.175; MeOH) - 
EUP-28 (4) 17.6 -152 (t3) (0.1) 212-215 
EUP-29 (8) 25.0 -42 (t3) (0.1) - 
EUP-32 (5) 5.2 -113 (t3) (0.1) - 
EFAL-3 (12) 24.8 -68 (t5) (0.1) 165-167 
EFAL-4 (13) 3.7 -4 (t5) (0.1) - 
EFAL-6 (14) 3.2 -31 (t5) (0.05) - 
EFAL-7 (15) 3.5 -35 (t5) (0.1) - 
EFAL-19 (16) 4.9 +60 (t2) (0.1) - 
EFAL-20 (17) 10.6 +60 (t2) (0.1) 225-228 
EFAL-21 (18) 4.8 +59 (t2) (0.1) 126-128 
Optical rotation in chloroform at t1 = 26 °C, t2 = 25 °C, t3 = 22 °C, t4 = 28 °C and t5 = 28.5 °C 
 
The most useful data regarding the chemical structures of the compounds were obtained from 
advanced 1D and 2D NMR experiments, including 1H NMR, JMOD, 1H–1H COSY, NOESY, HSQC and 
HMBC spectroscopy.  
The high-resolution MS measurements revealed the exact masses and molecular compositions of 
the compounds (Table 2). The fragment ions observed indicated the sequential loss of esterifying 
acids (acetic, benzoic, nicotinic and isobutanoic acids) from the parent ions. 
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Table 2. MS data on the isolated new compounds 
 
EPAN-3 
The molecular formula of EPAN-3 (1) was assigned as C24H32O4 via ESIMS, HREIMS and NMR 
investigations. The 1H NMR, JMOD and HSQC spectra of EPAN-3 suggested a diterpene skeleton with 
20 carbon atoms (4 methyls, 3 methylenes, 7 methine groups and 6 quaternary carbons) and typical 
signals for 1 benzoyl and 1 isobutanoyl group. The carbon and proton signals exhibited 2 olefin 
groups (C-1, C-2 and C-6, C-7) at δC 160.2, 136.8, 136.6 and 131.6 ppm and at δH 7.57 and 5.66 ppm. 
The signal at δC 210.0 revealed 1 keto group (C-3) and those at δC 69.8 and δH 4.72 1 isolated O-
Compound M.W. MS MS fragments (m/z) 
EPAN-3 (1) 506 ESIMS 529 [M+Na]+, 507 [M+H]+, 385 [M+H–C6H5COOH]
+, 297 [385–
C3H7COOH]
+ 
HREIMS 384.2304 [M–C6H5COOH]
+ (calcd. for C24H32O4, 384.2301) 
EPAN-7 (2) 520 HREIMS 520.2829 [M]+ (calcd. for C32H40O6, 520.2825) 
EUP-18 (6) 762 HRESIMS 763.3075 [M + H]+ (calcd for C40H47O13N2,  763.3073), 640 [(M + 
H) – C6H5NO2]
+, 580 [640 – AcOH]+, 598 [640 – CH2CO]
+, 538 
[598 – CH3COOH]
+, 478 [538 – CH3COOH]
+, 418 [478 –
 CH3COOH]
+, 312 [(M + H) – C6H5NO2 – 4 × CH3COOH –
 (CH3)2CHCOOH]
+, 295 [312 – H2O]
+ 
EUP-20 (3) 798 HRESIMS 821.3204 [M+Na]+ (calcd for C38H54O18Na, 821.3208). 
EUP-23 (7) 727 HRESIMS 728.3264 [M + H]+ (calcd for C38H50O13N, 728.3277), 626 [686 –
 AcOH]+, 566 [626 – AcOH]+, 506 [566 – AcOH]+, 418 [566 –
 iBuOH]+, 295 [418 – NicOH]+ 
EUP-28 (4) 654 HRESIMS 677.2554 [M + Na]+ (calcd for C35H42O12Na, 677.2568), 672 [M 
+ NH4]
+, 473 [533 – AcOH]+, 413 [473 –AcOH]+, 353 [413 –
 AcOH]+, 293 [353 – AcOH]+ 
EUP-29 (8) 669 HRESIMS 670.3204 [M + H]+ (calcd for C36H48O11N, 670.3222) 
EUP-32 (5) 562 HRESIMS 585.2664 [M + Na]+ (calcd for C30H42O10Na, 585.2675) 
EFAL-3 (12) 492 HRESIMS 515.2984 [M + Na]+ (calcd. for C28H44O7Na, 515.2985) 
EFAL-4 (13) 654 HRESIMS 677.2935 [M + Na]+ (calcd. for C36H46O11Na, 677.2938) 
EFAL-6 (14) 626 HRESIMS 649.2999 [M + Na]+ (calcd. for C35H46O10Na, 649.2989) 
EFAL-7 (15) 712 HRESIMS 735.2989 [M + Na]+ (calcd. for C38H48O13Na, 735.2993) 
EFAL-19 (16) 840 HRESIMS 863.3473 [M + Na]+ (calcd. for C44H56O16Na, 863.3466) 
EFAL-21 (18) 826 HRESIMS 849.3307 [M + Na]+ (calcd. for C43H54O16Na, 849.3310) 
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substituted methylene group (C-20). A broad singlet at δH 5.5 identified a hydroxy group (9-OH). 3 
spin systems of correlated protons were identified by means of the gradient COSY spectrum: =CH–
CH–CH–CH2– (δH 7.57, 3.32, 2.46, 2.93 and 2.22), =CH–CH–CH– (δH 5.66, 2.16 and 0.83) and –
CH(CH3)–CH2– (δH 1.43, 0.92 and 2.13/1.55). Tertiary methyls and quaternary carbons joined these 
structural moieties. The correlations of the HMBC spectrum confirmed these assignments. The 
chemical shifts δC 62.8 and 69.8 showed O-substitutions on C-13 and C-20. The binding of the 
benzoyl group at C-20 was indicated by at the HMBC correlation of the signals at δC 166.2 and δH 
4.72. The position of the hydroxy group was deduced on the basis of biogenetic considerations and 
literature data on structurally related compounds. A NOESY experiment demonstrated the relative 
configuration of the stereogenic centres of EPAN-3. The β position of the H-5β, H-8, H-11, H-12β and 
17-CH3 protons was revealed by the NOE interactions among these protons. The nuclear Overhauser 
effects (NOE) between 16-CH3 and H-14, H-14 and 9-OH indicated the α arrangement of all these 
proton, methyl and hydroxy groups. 
  
1 2 
EPAN-7 
EPAN-7 (2), a colourless oil, has the molecular formula C32H40O6, determined via the quasimolecular 
ion peak at m/z 520.2829 [M]+ in the HREIMS and supported by the hydrogen and carbon atom 
counts in the NMR spectra. The 1H NMR and JMOD spectra proved closely comparable to those of 
EPAN-3; the dissimilarity is an isovaleroyl ester group instead of an isobutanoyl on C-13 in EPAN-7.  
 
EUP-20 
EUP-20 (3, esulatin H), obtained as an amorphous solid with the molecular formula C38H54O18, was 
shown on the basis of a detailed NMR study to be a polyacylated derivative of a jatrophane 
compound. Seven acetate groups [δH 2.27 s, 2.24 s, 2.20 s, 2.15 s, 2 × 2.13 s and 1.80 s; δC 170.7, 3 × 
170.3 and 3 × 169.5 (CO) and 22.7, 22.5, 22.0, 21.5, 2 × 21.2 and 20.5 (CH3)] and 1 isobutanoyl group 
(δH 2.60 m, 1.25 d and 1.24 d; δC 176.1, 34.6, 19.5 and 18.5) were proved by the 
1H and 13C NMR 
spectra. Four methyl signals (1.67 s, 1.44 d, 1.40s and 0.95 s) were observed in the 1H NMR 
spectrum. The 1H NMR, JMOD and HSQC spectra of EUP-20 reflected a skeleton consisting of 20 
carbons (4 methyls, 2 methylenes, 9 methines and 5 quaternary carbons). The signal at δH 7.39 s, 
31 
which showed no correlation in the HSQC spectrum to any carbon, was assigned to a hydroxy group 
(14-OH). From the 1H–1H COSY and HSQC spectra of EUP-20, 3 sequences of correlated hydrogen 
atoms could be extracted, –CHR–CH–CHR– (δH 5.80, 4.58 and 6.38), –CHR–CHR–CHR– (δH 7.23, 6.30 
and 5.41) and –CH–CHR–CH(CH3)– (δH 3.80, 5.80, 2.98 and 1.44), and 1 exomethylene group (δH 6.39 
s and 6.06 s, δC 123.5). These fragments, tertiary methyls and quaternary carbons were connected 
by means of an HMBC experiment. The positions of the ester groups were also established via the 
HMBC spectra and the literature data on structurally analogous compounds. The relative 
configuration of EUP-20 was determined via a NOESY experiment. As reference point, the position of 
H-4, was chosen to be α. NOEs between hydrogen pairs H-4/H-3, H-4/H-7, H-4/OH-14, OH-14/13-
CH3, H-20/H-1α and H-7/10-CH3 (C-19) were indicative of the α orientation of these hydrogen atoms. 
NOEs between hydrogen pairs 10-CH3 (C-18)/H-9, H-9/H-8, H-9/H-11, H-11/H-12, H-12/H-8, H-12/H-
13, H-1β/H-16 required their β position. All of the above evidence proved the structure 3 for EUP-20. 
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EUP-28 
EUP-28 (4, esulatin I) was isolated as white crystals with the molecular formula C35H42O12. From the 
1H NMR and JMOD spectra, 5 ester residues were identified as 1 benzoate (δH 8.11, 7.40 and 7.53; δC 
165.6, 131.1, 130.0, 128.1 and 132.6) and 4 acetate [δH 2.21, 2.18, 2.15 and 2.07; δC 170.2, 169.9, 
169.6 and 169.2 (CO) and 22.9, 21.4, 20.7 and 20.1 (CH3)] groups. The diterpene core was found to 
contain 4 methyls, 3 methylenes, 7 methines, 6 quaternary carbons and 2 keto functions (δC 209.3 
and 209.5). The 1H–1H COSY of EUP-28 revealed the presence of the structural fragments –CH2–CR–
CH–CH–CH–C(=CH2)–CH–CH2– (–C-1–(C-17)–C-8–), and –CH=CH–CH(CH3)– (–C-11–C-13(C-20)–). 
Their connectivities were determined from the long-range C – H correlations observed in the HMBC 
spectrum. The relative configuration of EUP-28 was established on the basis of the NOESY 
correlations between H-4/H-1α, H-4/H-2’,6’, H-4/H-7, H-7/H-12, H-12/H-20, H-12/H-19 and H-8β/H-
11, H-11/H-13, H-13/H-5, H-5/H-11, H-8β/H-18 and H-11/H-18, thereby confirming structure 4 for 
EUP-28. 
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EUP-32 
EUP-32 (5, esulatin J) was obtained as a colourless, amorphous solid. The 1H NMR and JMOD spectra 
of EUP-32 revealed 3 acetyls and 1 isobutanoyl group. The 1H NMR and JMOD spectra of esulatin J 
were very similar to those of esulatin I, except for the appearance of an H-2 signal and a change in 
the chemical shift of C-2 (δC 38.3 in EUP-32, 87.2 in EUP-28). From the COSY, HSQC and HMBC 
analysis of EUP-32, it was apparent that esulatin I and J are based on the same parent system and 
differ only in the substituents on C-2 and C-7. The absence of acetyl and benzoyl signals and the 
appearance of signals of a further isobutanoyl indicated the replacement of one of the acetyl 
residues with an isobutanoyl group. Comparison of the NOESY spectra of EUP-28 and EUP-32 
showed the same relative configuration for these compounds. 
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EUP-18 
EUP-18 (6, esulatin K), with molecular formula C40H46O13N2, was isolated as an amorphous solid. The 
1H NMR and JMOD spectra showed characteristic signals for 2 nicotinoyl (δH 9.31, 8.44, 7.37 and 
8.77; 9.18, 8.13, 7.30, 8.77; δC 164.1, 151.2, 125.8, 137.5, 123.3, 152.9; 164.3, 150.9, 127.4, 136.7, 
123.5 and 153.6) and 4 acetyl [δH 2.19, 2.18, 2.16 and 1.52; δC 168.8, 169.5, 169.6 and 170.3 (CO) 
and 20.4, 21.1 and 2 × 21.3 (CH3)] groups. Examination of the 2D NMR data on EUP-18 revealed that 
it was based on the same parent system as esulatin H and I, with differences in the esterification 
pattern: in the case of EUP-18, the 9-keto group was replaced by a nicotinoyl substituent. The 
relative configuration of esulatin K was determined by a NOESY experiment. The NOEs between H-
4/H-1α, H-4/H-3, H-4/H-7 and H-7/H-18 indicated the α-orientation of these protons. The cross-
peaks of β-oriented protons could be observed between H-1β/H-16, H-5/H-13, H-13/H-11, H-11/H-9 
and H-9/H-19. 
 
EUP-23 
EUP-23 (7, esulatin L) was isolated as an amorphous solid. The molecular formula of this compound 
was determined as C38H49O13N by means of HRESIMS. The 
1H NMR and JMOD spectra exhibited 
typical signals for 1 nicotinoyl group (δH 9.20, 8.22, 7.38 and 8.78; δC 164.0, 151.1, 125.7, 137.0, 
123.3 and 153.6) and 4 acetyl [δH 2.18, 2.16, 2.15 and 2.13; δC 170.5, 170.2, 169.5 and 168.9 (CO) 
and 21.3, 21.2, 21.1 and 21.0 (CH3)] groups. Analysis of the 
1H–1H COSY, HSQC and HMBC spectra 
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revealed similarity between esulatin K and L. The difference was that in EUP-23 the 2-O-nicotinoyl 
group was replaced by an acetyl group and the 7-O-acetyl group by an isobutanoyl group. The 
relative configuration of esulatin L, established via a NOESY experiment, was found to be the same 
as that of EUP-18 and EUP-23. 
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EUP-29 
EUP-29 (8, esulatin M) was isolated as an amorphous solid with the molecular formula C36H47O11N. 
From the 1H–1H COSY, HSQC, HMBC and NOESY spectra, it was evident that EUP-23 and EUP-29 
differ only in the lack of one substituent, an acetyl group on C-2, in esulatin M. 
 
EUP-26 
EUP-26 (9) was found to be identical in all of its characteristics, including the 1H and 13C NMR 
spectral data, with the jatrophane diterpene isolated earlier from Euphorbia peplus.25,121 
  
10 11 
EUP-13 and EUP-17 
The 1H and 13C NMR spectroscopic investigations proved that EUP-13 (10, salicinolide) was a 17-ethyl 
bis-homojatrophane-type lactone, salicinolide, and EUP-17 (11, euphosalicine) was the modified 
jatrophane euphosalicin. Both compounds were described previously from Euphorbia salicifolia.29,30 
 
EFAL-3 
EFAL-3 (12) was obtained as white crystals. Its molecular formula was determined to be C28H44O7. 
From the 1H NMR and JMOD spectra, 2 ester residues were identified as 1 hexanoyl [δH 2.41 (2H), 
1.67 (2H), 1.31 (4H), and 0.89 (3H); δC 175.8, 34.6, 31.3, 24.9, 22.3 and 13.9] and 1 acetyl [δH 2.15; δC 
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170.2 (CO) and 21.1 (CH3)] group. Additionally, the 
1H NMR spectrum showed signals of 4 methyls 
(δH 1.18, 1.05, 0.98 and 0.96). The 
1H NMR, JMOD and HSQC spectra of EFAL-3 identified a diterpene 
skeleton containing 20 carbon atoms (4 methyls, 4 methylenes, 8 methines and 4 quaternary 
carbons). The 1H–1H COSY spectrum indicated 2 structural fragments with correlated protons: –CH2–
CH(CH3)–CHR–CH–CHR– (δH 2.40, 1.50, 2.18, 0.98, 5.28, 2.60 and 3.45) and –CH2–CH2–CH–CH–CH– 
(δH 2.08, 1.70, 0.72, 0.70, 0.51 and 2.69). The presence of a gem-dimethyl-substituted cyclopropane 
ring was indicated by signals of a quaternary carbon (δC 18.3) and the signals at δH 0.70 m, 0.51 t, 
1.05 s, 0.96 s and δC 25.5, 19.0, 28.5 and 15.2. The connectivities of the 2 structural fragments, 
including the gem-dimethyl-substituted cyclopropane ring, were determined from the C–H 
correlations in the HMBC spectrum. The long-range C–H correlations of the quaternary carbons (δC 
52.3, 18.3, 85.9 and 80.3) with protons of the 2 structural fragments established a pentacyclic 
premyrsinane diterpene with O-functionalities on C-3, C-5, C-14 and C-15. A saturated furan ring 
through C-17 and C-13 was determined by analysis of the HMBC spectrum. This kind of furan ring is 
typical for many myrsinane, cyclomyrsinane and premyrsinane esters. Moreover, the positions of 
the ester groups were determined from HMBC experiment. The long-range correlations indicated 
the presence of an n-hexanoyl group on C-3 and an acetyl group on C-14. Two proton signals, at δH 
3.75 and 1.58, which exhibited no correlations to any carbon in the HSQC spectrum, were assigned 
to 2 hydroxy groups (on C-5 and C-15). The relative configuration of EFAL-3 was investigated in a 
NOESY experiment. It was deduced by starting from the α-position of the proton at the ring junction 
(H-4), characteristic of many types of Euphorbiaceae diterpenes. The NOEs between H-11/H-9, H-
11/H-17b and H-2/H-1α proved the α-orientation of all these protons. The NOE interactions 
between H-5/H-8β, H-5/H-12, H-5/OH-15 and H-12/10-CH3 (C-19) indicated the β-orientation of 
these protons. 
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EFAL-4 
EFAL-4 (13), with molecular formula C36H46O11, was isolated as a colourless amorphous solid. On the 
basis of NMR analyses, 3 acetyl [δH 2.16, 2.07 and 1.43; δC 170.5, 169.3 and 168.5 (CO) and 22.7, 
21.2 and 21.1 (CH3)], 1 benzoyl (δH 7.98, 7.41 and 7.54; δC 166.3, 133.0, 130.4, 130.0 and 128.3) and 
1 propanoyl group (δH 2.25, 2.21 and 1.03; δC 174.1, 27.7, 9.0) were identified. Furthermore, the 
resonances of 4 methyls, 3 methylenes, 9 methines and 4 quaternary carbons were shown in the 
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JMOD spectra. The 1H–1H COSY of EFAL-4 revealed the structural elements –CH2–CH(CH3)–CHR–CH–
CHR– (C-1–C-2(C-16)–C-3–C-4–C-5) and –CHR–CH2–CH–CH–CH– (C-7–C-12). The connection of these 
partial structures was shown by the HMBC spectra. It emerged that EFAL-4 is also a premyrsinane 
derivate. The 1H and 13C chemical shifts and coupling constants of EFAL-3 and EFAL-4 were very 
similar, except for the signals of C-7 and H-7. For EFAL-4, the δH-7 4.85 and δC-7 73.7 signals clearly 
demonstrated O-substitution on C-7. The locations of the ester groups were identified through an 
HMBC experiment. A careful comparison of the NOESY spectra of EFAL-3 and EFAL-4 suggested the 
same stereochemistry for these compounds. The β-orientation of the 7-benzoyl group in EFAL-4 was 
determined from the NOESY cross-peak between H-7 and H-8α, H-9, H-17b. 
 
EFAL-6 
EFAL-6 (14) was obtained as a colourless amorphous solid with the molecular formula C35H46O10. 
From the 1H NMR and JMOD spectra, 4 ester residues were identified as 2 acetyl, 1 isobutanoyl and 
1 benzoyl groups. Additionally, these spectra and the 1H–1H COSY, HSQC and HMBC exhibited 
resonances closely related to those of EFAL-4, and it was obvious that compounds EFAL-4 and EFAL-
6 differ only in the substitution on C-3 and C-5, i.e. the propanoyl residue should be replaced by an 
isobutanoyl group and an acetyl group by a hydroxy group. A careful comparison of the NOESY 
spectra of EFAL-4 and EFAL-6 led to the same relative configuration being inferred for these 
compounds. 
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EFAL-7 
EFAL-7 (15) was isolated as a colourless amorphous solid. The HRESIMS and NMR analyses indicated 
the molecular formula C38H48O13. The 
1H NMR and JMOD spectra of this compound revealed the 
presence of 4 acetyl [δH 2.21, 2.11, 2.05 and 1.27; δC 170.0, 169.9, 169.4 and 168.3 (CO) and 22.9, 2 x 
21.2 and 20.9 (CH3)], 1 benzoyl (δH 7.95, 7.53 and 7.41; δC 166.2, 133.2, 132.9, 130.4 and 128.4) and 
1 propanoyl group (δH 2.33, 2.25 and 1.09; δC 174.0, 23.6, 8.9). Analysis of the 
1H–1H COSY, HSQC 
and HMBC spectra of EFAL-7 showed that this compound has a similar parent system to that of 
EFAL-3, EFAL-4 and EFAL-6. The spectroscopic data were especially similar to those of EFAL-6, the 
main difference between these compounds being the presence of a further O-functionality in 
EFAL-7. A careful comparison of the NOESY spectra of EFAL-7 and the other compounds indicated 
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the same stereochemistry. As concerns the chiral centre C-17, the strong NOESY cross-peak between 
H-4/H-17 proved the configuration of C-17 as depicted in structural formula 15. 
 
EFAL-19 
EFAL-19 (16), with molecular formula C44H56O16, was isolated as an amorphous solid. The 
1H NMR 
and JMOD spectra exhibited typical signals for 4 acetyl [δH 1.97, 2.09, 2.12 and 2.16; δC 169.7, 168.8, 
170.2 and 168.0 (CO) and 20.8, 21.6, 21.3 and 23.1 (CH3)], 1 benzoyl (δH 7.89, 7.53 and 7.40; δC 
164.7, 133.0, 130.3, 129.6 and 128.3), 1 isobutanoyl (δH 2.39, 1.05 and 0.99; δC 175.4, 34.1, 18.9 and 
18.4), and 1 2-methylbutanoyl groups (δH 2.60, 1.70, 1.55 and 0.87; δC 174.7, 40.9, 27.0 and 11.0). 
Furthermore, the resonances of 3 methyls were identified in the 1H NMR spectrum. Informative 
signals at δH 4.28 and 3.63 indicated the presence of a tetrahydrofuran ring of a myrsinane-type 
skeleton. The JMOD and HSQC spectra (Figure 6) suggested that the skeleton consists of 20 carbons: 
3 methyls, 3 methylenes, 8 methines and 6 quaternary carbons. 
The structural elements determined via the 1H–1H COSY spectrum (Figure 7) were connected by 
inspection of the long-range C–H correlations observed in the HMBC spectrum (Figure 8). The 2- and 
3-bond correlations between the quaternary carbon C-2 and H-1 and H-16, between the quaternary 
C-15 and H-1 and H-3, and between the C-4 and H-1 and H-5 signals revealed that structural 
fragment A, together with quaternary C-2 and C-15, forms a 5-membered ring. 
 
Figure 6. HSQC spectrum of 16. 
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Figure 7. 1H–1H COSY spectrum and correlations (▬) of 16. 
HMBC cross-peaks between C-6 and H-5, H-8 and H-12, between C-7 and H-8 and between C-10 and 
H-11, H-12 and H-19 established a cyclomyrsinane diterpene with O-functionalities on C-2, C-3, C-5, 
C-7, C-8, C-10, C-14 and C-15. Additionally, the heteronuclear long-range coupling between H-17a 
and C-13, and between C-5 and H-12 and H-17, indicated an O-bridge between C-17 and C-13. The 
positions of the ester groups were also determined via the HMBC experiment. These C–H 
correlations exhibited the presence of acetyl groups on C-5, C-10, C-14 and C-15, an isobutanoyl 
group on C-3, and a 2-methylbutanoyl group on C-8. The positions of 2-OBz, 10-OAc and 15-OAc 
groups were also suggested by the NOESY correlations. 
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Figure 8. HMBC spectrum and 1H–1H COSY (▬) and HMBC (C→H) correlations of 16. 
The stereochemistry and relative configuration of EFAL-19 were studied by means of a NOESY 
experiment (Figure 9). The relative configuration of EFAL-19 was deduced by starting from the α-
orientation of H-4. Cross-peaks between H-4/H-3, H-4/H-14, H-4/H-16, H-3/5-OAc H-14/H-1α and H-
16/H-1α proved the β-orientation of the 3-O-isobutanoyl, H-5, 14-O-acetyl and 2-O-benzoyl groups. 
The NOEs between H-5/H-12 and H-12/H-20 showed the β-orientation of these protons. 
Additionally, the NOEs between 5-OAc/H-8, H-8/H-9, H-9/H-18 and H-18/H-11 confirmed the α-
orientation of all these protons. NOESY cross-peaks between H-4/H-17a and H-11/H-17b proved that 
the –CH2–O– bridge is oriented below the plane of the carbon skeleton. 
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Figure 9. Diagnostic NOESY correlations for compound 16. 
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EFAL-20 
EFAL-20 (17) was obtained as white crystals. It was found to be identical in all of its characteristics, 
including the 1H NMR spectral data, with SPr4 isolated earlier from Euphorbia prolifera.181 
 
16 17 18 
EFAL-21 
EFAL-21 (18), with molecular formula C43H54O16, was isolated as white crystals. The 
1H NMR and 
JMOD spectra of EFAL-21 revealed 4 acetyl [δH 1.96, 2.09, 2.12 and 2.15; δC 169.8, 168.8, 170.2 and 
168.1 (CO) and 20.8, 21.6, 21.3 and 23.0 (CH3)], 1 benzoyl (δH 7.88, 7.52 and 7.39; δC 164.7, 133.0, 
130.3, 129.6 and 128.3), and 2 isobutanoyl groups (δH 2.37, 1.05 and 0.98, and 2.75, 1.25 and 1.22; 
δC 175.4, 34.1, 18.9 and 18.3, and 175.1, 34.4, 20.3 and 18.5). After the 
1H and 13C NMR data on 
EFAL-21 had been assigned by analysis of its 1H–1H COSY, HSQC and HMBC spectra, it was obvious 
that EFAL-21 and EFAL-19 are based on the same parent system and differ only in the substitution 
on C-8 (replacement of a 2-methylbutanoyl residue with an isobutanoyl group). A careful 
comparison of the NOESY spectra of EFAL-19 and EFAL-21 led to the conclusion that the 
stereochemistry of these compounds is the same. 
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5. DISCUSSION 
Phytochemical investigations of E. pannonica, E. esula, and E. falcata led to the isolation of 18 
diterpenes, including 14 new natural products. The structures were established by means of spectral 
analyses as esters of jatrophane, tigliane, premyrsinane and cyclomyrsinane-type diterpenes. 
Biological investigations revealed that some of the isolated compounds possess noteworthy 
pharmacological activities (antiproliferative and MDR-reversing). 
5.1. Isolation of diterpenes 
 Screening of E. pannonica and E. falcata led to the conclusion that the lipophilic extracts 
contain a number of diterpene esters, which can be enriched by polyamide OCC, mainly in the 60% 
aqueous MeOH fraction. The purification of the compounds generally requires the involvement of 
multistep separation methods because the plants produce complex mixtures of esters of the same 
diterpene nucleus (these may display very similar chromatographic characters), and the compounds 
occur merely in low quantities in the plants. The diterpene content of E. esula was known from 
previous literature data; screening for diterpene content was not needed. 
 The fresh (frozen) whole plant materials were extracted with MeOH at room temperature by 
percolation. MeOH, an amphipolar solvent, was suitable for the extraction of both lipophilic and 
polar compounds. 
 In the initial step of separation, liquid–liquid extraction with CHCl3 was applied in order to 
remove the polar constituents. The purification was continued with classical OCC. In accordance 
with the screening investigations, polyamide proved to be suitable as stationary phase for the 
preparative work, with the use of MeOH–H2O solvent systems. The 20–60% MeOH fractions were 
rich in diterpenes, the 80% MeOH fractions contained mainly triterpenes and chlorophyll. 
 In the following steps, even more selective methods (VLC, RPC, PLC and HPLC) were applied. 
After polyamide OCC, adsorption chromatography on silica gel was used in all experiments. VLC and 
RPC separations of the diterpene fractions afforded crude fractionations of the main components. 
For final purification, NP- and RP-HPLC were applied since these were the most effective and most 
selective separation methods. HPLC provided mild conditions for polyester-type (light- and heat-
sensitive) diterpenes. 
 The preparative work was completed with analytical TLC on silica gel with various solvent 
systems. The aims of the TLC analysis were to model the separation methods, to combine fractions, 
and to check the purity of the isolated compounds. The detection was carried out in UV light at 254 
nm, followed by spraying with cc. H2SO4. 
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 As a result of the isolation procedure, 18 compounds, occurring in low concentration, were 
obtained from the multicomponent samples. Usually, compounds with very similar structures were 
separated per plant, most of the isolated components differing from each other only in the ester 
groups, and EPAN-3 (1) and EPAN-7 (2), EUP-23 (7) and EUP-26 (9), and EFAL–19 (16) and EFAL-20 
(17) differing in only 1 substituent. After extensive chromatographic purification, 2 compounds were 
isolated from E. pannonica (EPAN-3 and EPAN-7), 9 from E. esula (EUP-13, EUP-17, EUP-18, EUP-20, 
EUP-23, EUP-26, EUP-28, EUP-29 and EUP-32), and 7 from E. falcata (EFAL-3, EFAL-4, EFAL-6, EFAL-7, 
EFAL-19, EFAL-20 and EFAL-21). 
5.2. Structure elucidation 
 The isolated compounds are amorphous solids or crystals. They are optically active. The 
structures of the isolated compounds were elucidated by means of spectroscopic methods. From 
HRESIMS measurements, the molecular compositions were determined. The most useful data 
concerning the chemical structures were furnished by 1D and 2D NMR spectroscopy. From the 1H 
and 13C NMR, 1H–1H COSY, HSQC and HMBC experiments, the constitutions of the compounds were 
determined, and then, with the aid of the NOESY spectra, the relative configurations were 
elucidated. In the isolated compounds, the number of asymmetric carbons was 8–13, and all of 
them were characterized stereochemically. As a result of the NMR studies (1H NMR, JMOD, 1H–1H 
COSY, HSQC and HMBC), complete 1H and 13C assignments were made for the characterization of the 
compounds.  
 Structurally, 9 of the compounds are jatrophanes or modified jatrophanes, 2 are tiglianes, 4 are 
premyrsinanes and 3 are cyclomyrsinane-type compounds. EPAN-3 (1) and EPAN-7 (2) are 
derivatives of 4,12-dideoxyphorbol, a diterpene alcohol that is very rare in the plant kingdom. 
Furthermore, EPAN-7 (2) is substituted with an isovalerianate group, which was found for the first 
time in the group of tigliane diterpenes.  
 EUP-18 (6), EUP-23 (7), EUP-29 (8), EUP-26 (9) and EUP-17 (11) isolated from E. esula contain a 
nicotinoyl group, and can therefore be regarded as pseudoalkaloids. The diversity of the ester 
groups is characteristic for the members of EFAL series, e.g. in EFAL-19 (16) 4 (acetyl, isobutanoyl, 2-
methylbutanoyl and benzoyl), and in EFAL-4 (13), EFAL-6 (14), EFAL-7 (15), EFAL-20 (17) and EFAL-21 
(18) 3 different ester groups were found. EUP-20 (3) is the most highly esterified jatrophane 
diterpenoid, with 8 ester groups. Besides ester groups, hydroxy and keto functions are also present 
in the molecules. In EUP-20 (3), an ether function is to be found between C-11 and C-14, and it 
therefore possesses an unusual heterocyclic ring system. Such compounds have been isolated earlier 
only from E. kansui and E. esula.173,182,183 The EUP series is stereochemically homogeneous, 
characterized by 2β-methyl, 13α-methyl and 3β, 7β, 5α, 8α, 9α and 15β-acyl substitution. 
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 In the EFAL series, EFAL-7 (15) contains a rare hemiacetal moiety, such diterpenes being very 
rare in the Euphorbiaceae. EFAL-3 (12), EFAL-4 (13), EFAL-6 (14) and EFAL-7 (15) are the first known 
premyrsinane-type diterpenes containing an acyl moiety instead of a keto group on C-14. 
Biogenetically, premyrsinanes can be derived from epoxylathyranes by intramolecular cyclization, 
and they are the precursors of cyclomyrsinanes. Cyclomyrsinane diterpenes are very rare in the 
plant kingdom; only 7 compounds have been isolated previously from other Euphorbia species. 
Moreover, EFAL-19 (16) and EFAL-20 (17) are substituted with an ester group at C-2, which is also 
unprecedented. Similarly to the EUP series, the EFAL series is stereochemically homogeneous, but 
interestingly the configuration of C-16 is β in the premyrsinanes (EFAL-3, EFAL-4, EFAL-6 and EFAL-7) 
and α in the cyclomyrsinanes (EFAL-19 – EFAL-21). 
5.3. Chemotaxonomical significance 
 Diterpenes are considered to be important taxonomic markers of the Euphorbiaceae family, 
because of its limited occurrence and structural diversity. 
 On the basis of the diterpene composition, E. esula displays a close relationship with E. 
salicifolia; these species belong in the same section. They contain the same main diterpene 
components, esulatin A, EUP-13 (salicinolide, 10) and EUP-17 (euphosalicine, 11) and other 
jatrophane diterpenes differing only in the esterification. 
 The diterpenes isolated from E. esula in our experiment are not identical with those obtained 
by other workgroups.16,104,105,147-150,153 The samples of different origins (China, North America and 
Hungary) contain different diterpenes. In the EUP series obtained from the Hungarian collection, the 
alcohol core of the compounds was different. In this species, the morphological diversity 
(characteristic of E. esula) is manifested in the chemical features (the diterpene profile), too. 
 The chemical constituents of E. pannonica and E. falcata have not been investigated previously. 
 All of the isolated diterpenes were detected for the first time in the given plants. 
5.4. Biological activities 
The isolated compounds were tested for their antitumour and MDR-reversing activities. 
 Antitumour activity: As many experimental data have been published in the past few years on 
the antitumour activities of Euphorbiaceae diterpenes,157-168 the antiproliferative activities of the 
isolated diterpenes, together with 5 jatrophane diterpenes (esulatins A, B, D–F; Figure 10) identified 
in our earlier experiments were evaluated against human tumour cell lines [HeLa (cervical 
adenocarcinoma), Ishikawa (endometrial adenocarcinoma), MCF7 (breast epithelial 
adenocarcinoma) and A431 (skin carcinoma)] using the MTT test and with cisplatin as positive 
control. 
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Figure 10. Diterpenes isolated previously from E. esula 
The results presented in Table 3 revealed that the isolated diterpenes possess different cell 
growth-inhibitory activities; substantial effects were recorded only at the higher tested 
concentration: 30 µg/mL. EUP-32 (esulatin J, 5), and esulatins A and E were the most effective 
against all cell lines; especially EUP-32 (5) exhibited high cell growth-inhibitory activity on Ishikawa 
(98.4%, at 30 µg/mL) and MCF7 (81.4%, at 30 µg/mL) cells. 
Table 3. Inhibition (%) of tumour cell proliferation by Euphorbia diterpenes.a 
Compound HeLa Ishikawa MCF7 A431 
10 
µg/mL 
30 
µg/mL 
10 
µg/mL 
30 
µg/mL 
10 
µg/mL 
30 
µg/mL 
10 
µg/mL 
30 
µg/mL 
EUP-20 (3) 10.6 17.8 12.0 17.7 9.8 11.4 - - 
EUP-28 (4) 15.4 23.8 8.0 29.4 12,7 60.1 - - 
EUP-32 (5) 19.1 64.5 18.4 98.4 46.8 81.4 - - 
EUP-18 (6) 17.3 36.3 11.6 35.0 29.9 43.3 - - 
EUP-23 (7) 0.5 0.6 7.5 0.1 1.3 21.3 - - 
EUP-29 (8) 6.4 1.1 17.5 26.6 3.6 16.7 - - 
EUP-26 (9) 18.3 4.5 5.9 16.4 18.5 14.4 - - 
EUP-13 (10) 13.9 17.9 8.1 13.9 20.3 36.3 - - 
EUP-17 (11) 11.4 26.7 29.4 29.9 9.5 13.5 - - 
esulatin A 16.3 62.6 20.1 53.8 21.4 47.9 - - 
esulatin B 2.9 10.9 21.4 17.1 8.7 23.3 - - 
esulatin D 5.3 20.8 31.5 33.0 24.8 29.2 - - 
esulatin E 19.5 58.1 35.6 54.1 30.4 61.4 - - 
esulatin F 14.5 18.1 0.9 7.6 6.3 20.0 - - 
EFAL-3 (12) 12.8 60.4 - - 30.6 56.0 23.0 35.6 
EFAL-4 (13) 22.2 56.9 - - 21.1 49.1 36.2 81.4 
EFAL-6 (14) 25.8 83.9 - - 33.6 59.2 38.0 93.6 
EFAL-7 (15) 20.6 47.3 - - 25.9 38.9 39.2 69.1 
EFAL-19 (16) 21.9 33.3 - - 29.8 43.0 32.4 40.3 
EFAL-20 (17) 16.9 33.7 - - 17.3 53.3 38.9 45.1 
EFAL-21 (18) 18.1 14.1 - - 4.9 17.0 23.4 17.9 
a Positive control cisplatin: 12.4 µM (HeLa), 3.5 µM (Ishikawa and A431) and 9.6 µM (MCF-7). 
 
In the case of the diterpenes isolated from E. falcata (12-18), weak or moderate cell growth-
inhibitory activities were detected; substantial effects were recorded only at the higher tested 
concentration (30 µg/mL) for compound 14, which showed significant activity in all 3 cell lines 
[83.9% (HeLa), 93.6% (A431) and 59.2% (MCF7) at 30 µg/mL). Compound 13 exerted inhibitory 
activity on HeLa (56.95% at 30 µg/mL) and A431 (81.4% at 30 µg/mL) cells, while EFAL-3 (12) 
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exhibited 60.4% inhibitory activity on HeLa and 56.0% on MCF-7 cell lines at 30 µg/mL. Moreover, 
EFAL-7 (15) displayed antiproliferative activity only against A431 (69.1% at 30 µg/mL) cells, and 
EFAL-20 (17) had a weak effect on MCF7 (53.3% at 30 µg/mL). 
The structure–activity relationships are not easy to evaluate, because the structural variations 
within the set of compounds isolated from E. esula are very complex, stemming from the variations 
in the substitution on C-2, C-7 and C-9, from the nature of the ester groups on C-2, C-3, C-5, C-7, C-8 
and C-9, from the number and positions of the double bonds, and from the presence or absence of a 
keto or epoxy functionality. The most potent compounds found, esulatins I (EUP-28, 4), J (EUP-32, 5) 
and E, are tetra- or pentaesters of jatrophane polyols, which contain a keto group on C-9. Moreover, 
esulatin A, containing an epoxy group on C-11–C-12, also proved effective against all 3 cell lines. Of 
the components of E. falcata, the premyrsinanes (12-15) showed higher cell growth-inhibitory 
activities than those of the cyclomyrsinanes. Among them, EFAL-7 (15) is the only one substituted 
with a hemiacetal moiety and exhibiting high antiproliferative activity on A431 cells. 
 MDR-reversal activity: The discovery of jatrophane diterpenes as a new class of potent 
inhibitors of P-gp has led to increasing interest in research on this type of compounds. Many 
powerful inhibitors have been identified among jatrophane and modified jatrophane diterpenes, 
which are promising compounds for drug development because of their manifold higher potencies 
than those of the positive controls, cyclosporin A or verapamil. 
The investigation of the compounds for their capacity to inhibit rhodamine 123 (a fluorescent 
dye) efflux by MDR mouse lymphoma cells showed that the isolated diterpenes differ significantly in 
their inhibition of the efflux pump activity of P-gp in tumour cells (Table 4). Within the set of EUP 
compounds investigated, esulatin J (EUP-32, 5) [fluorescence activity ratio (R) = 52.5 at 40 μg/mL] 
and esulatin M (EUP-29, 8) (R = 119.9 at 40 μg/mL), and in the EFAL series EFAL-4 (13) (R = 74.5 at 20 
μg/mL), EFAL-6 (14) (R = 69.3 at 20 μg/mL), EFAL-7 (15) (R = 52.9 at 20 μg/mL), EFAL-19 (16) (R = 52.7 
at 20 μg/mL) and EFAL-20 (17) (R = 62.3 at 20 μg/mL) were found to be the most powerful inhibitors 
of efflux-pump activity. Their efficacy was 2-5-fold higher than that of the standard modulator 
verapamil, taken as a positive control (R = 23.2 at 10 μg/mL), and all of these compounds therefore 
appear to be promising leads for the development of drugs with which to overcome the MDR of 
cancer cells. 
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Table 4. Reversal of the MDR of mouse lymphoma cells by diterpenoids isolated from E. esula and E. 
falcata, and the results of the combination assay in the case of E. falcata 
Compound 
Conc. Fluorescence 
activity ratioa 
Compound 
Conc. Fluorescence 
activity ratioa 
FIX 
g/mL g/mL 
EUP-20 (3) 4 1.4 EFAL-3 (12) 2 0.9 0.54 
 40 1.0  20 1.4 
EUP-28 (4) 4 3.9 EFAL-4 (13) 2 23.4 0.23 
 40 19.9  20 74.4 
EUP-32 (5) 4 24.9 EFAL-6 (14) 2 29.8 0.40 
 40 52.5  20 69.3 
EUP-18 (6) 4 7.2 EFAL-7 (15) 2 12.6 0.73 
 40 19.8  20 52.9 
EUP-23 (7) 4 23.8 EFAL-19 (16) 2 46.2 0.15 
 40 36.4  20 52.7 
EUP-29 (8) 4 16.6 EFAL-20 (17) 2 36.9 0.32 
 40 119.9  20 62.3 
EUP-26 (9) 4 1.7 EFAL-21 (18) 2 1.2 0.38 
 40 2.3  20 5.2 
EUP-13 (10) 2 5.9     
 40 17.5     
EUP-17 (11) 4 1.9     
 40 12.3     
esulatin B 4 2.6     
 40 7.8     
esulatin D 4 4.6     
 40 15.2     
esulatin F 4 5.5     
 40 14.8     
esulatin A 4 2.0     
 40 1.9     
verapamil 10 23.2  22 8.77  
       
a Determination of fluorescence activity ratio (FAR): FAR = (MDR treated/MDR control)/(PAR 
treated/PAR control); (PAR = parental cell line) 
 
In the EFAL series, the high efficacy was supported by the data obtained in combination assays. 
All compounds were tested for their capacity to reduce the resistance of the MDR mouse lymphoma 
cell line to doxorubicin. The fractional inhibitory index (FIX) was obtained as the sum of the FIX 
values for each compound separately: FIX = FIXcompound+ FIXdoxorubicin. The FIX value of each compound 
is the fractional IC50 of the combined drugs divided by their individual IC50 as follows: FIX(compound) = 
IC50(compound + doxorubicin)/IC50(compound) and FIX(doxorubicin) = IC50(compound + doxorubicin)/IC50doxorubicin. As shown in 
Table 4, all the compounds exhibited a synergistic effect with doxorubicin, with combination index 
(FIX) values at 50% of growth of 0.54, 0.23, 0.40, 0.73, 0.15, 0.32 and 0.38 for compounds 12 to 18, 
respectively.  
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Among the members of the EUP series, EUP-32 (5) and EUP-29 (8) were the most active; both can 
be characterized by the absence of an ester group on C-2. Moreover, esulatin M (8) substituted with 
a nicotinoyl group on C-9 instead of a keto group (such as in 5) suggested that a 9-nicotinoyl group is 
also essential for high MDR-reversing activity. Among the premyrsinanes, EFAL-3 (12), which was 
inactive based on the FAR data and had low synergistic activity, differs structurally from the others 
because of the absence of the 7-OBz and 15-OAc groups, which therefore seem to be important for 
the activity of the compounds. The difference between 13 and 15 is an acetyl group on C-17, which 
seems to decrease the activity of the molecule. As regards the cyclomyrsinanes, EFAL-21 (18), 
without benzoyl substitution, possesses lower activity in the inhibition of the MDR1 pump (FAR 
results). The more active compounds 16 and 17 are also unsubstituted on C-17, similarly to 13, and 
differ from each other in the substitution on C-8, which seems to influence the long-term response 
observed in the results of the combination with doxorubicin, but not the short-term experiment, as 
shown in the accumulation of the rhodamine 123 data (Table 4). 
 From the above results, it could be concluded that the jatrophane, premyrsinane and 
cyclomyrsinane diterpenes could be therapeutically relevant natural products. 
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6. SUMMARY 
The aim of this work was the isolation, structure determination and pharmacological investigation of 
diterpenes from Euphorbia pannonica, E. esula and E. falcata. The isolation was carried out by a 
multistep separation procedure, including OCC, VLC, RPC, PLC and NP- and RP-HPLC. The structures 
of the isolated compounds were elucidated by means of spectroscopic methods (HR-MS and NMR). 
As a result of 1D (1H, 13C and JMOD) and 2D NMR studies (COSY, HSQC, HMBC and NOESY), complete 
1H and 13C assignments were made for the characterization of the compounds. 
As a result of our work, 2 new (1 and 2) diterpene polyesters were isolated from E. pannonica, 6 
new ones (3-8) and 3 known ones (9-11) from E. esula, and 6 new ones (12–16 and 18) and 1 known 
one (17) from E. falcata. Nine compounds are polyesters of jatrophane and modified jatrophane, 2 
of tigliane, 4 of premyrsinane and 3 of cyclomyrsinane-type. EUP-18 (6), EUP-23 (7), EUP-29 (8), 
EUP-26 (9) and EUP-17 (11) contain nicotinoyl group, and can therefore be regarded as 
pseudoalkaloids. The compounds are esterified with different acyl groups: acetyl, isobutanoyl, 
methylbutanoyl, propanoyl, hexanoyl, benzoyl or nicotionyl. EUP-20 (3) is the most highly esterified 
jatrophane-type diterpenoid, with 8 acyl groups. EFAL-19 (16) is the most diversely substituted 
diterpene, with 4 different ester groups (acetyl, isobutanoyl, 2-methylbutanoyl and benzoyl) in the 
molecule. 
EPAN-3 (1) and EPAN-7 (2) are derivatives of 4,12-dideoxyphorbol, a diterpene alcohol that is 
very rare in the plant kingdom. Furthermore, EPAN-7 (2) is substituted with an isovaleroyl group, 
which was found for the first time in this group of tigliane diterpenes. In EUP-20 (3), an ether 
function is to be found between C-11 and C-14, and it therefore possesses an unusual heterocyclic 
ring system. EFAL-7 (15) contains a rare hemiacetal moiety, such diterpenes being very rare in 
Euphorbiaceae. EFAL-3 (12), EFAL-4 (13), EFAL-6 (14) and EFAL-7 (15) are the first known 
premyrsinane-type diterpenes that contain an acyl moiety instead of a keto group on C-14. 
Moreover, EFAL-19 (16) and EFAL-20 (17) are substituted with an ester group on C-2, which is also 
unprecedented. 
On the basis of the diterpene composition, E. esula exhibits a chemotaxonomic relationship with 
E. salicifolia, as they contain the same main diterpene components, esulatin A, EUP-13 (10) and 
EUP-17 (11) and related compounds differing only in the esterification. E. esula can be characterized 
as displaying high morphological and chemical diversity.  
All of the diterpenes were detected for the first time from the investigated plants. The chemical 
constituents of E. pannonica and E. falcata have not been investigated previously. 
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The biological activities of most of the isolated compounds were investigated. Antiproliferative 
assays of some jatrophane (4, 5 and esulatins A and E), premyrsinane (12–15) and cyclomyrsinane 
(17) esters demonstrated strong activity against human tumour cells.  
The compounds in the EUP and EFAL series were examined for their MDR-reversing activity and it 
was concluded that they enhance drug retention significantly in tumour cells by inhibiting the efflux 
pump activity. EUP-32 (5), EUP-29 (8), EFAL-4 (13), EFAL-6 (14), EFAL-7 (15), EFAL-19 (16) and 
EFAL-20 (17) exhibited much stronger effects than that of the positive control verapamil. Moreover, 
members of the EFAL series displayed a synergistic effect with doxorubicin. The ability of 
premyrsinane and cyclomyrsinane diterpenes to act as potent modulators of MDR has been 
evaluated here for the first time. Our results open up new opportunities in the design and 
development of drugs to overcome the MDR of human cancers. 
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